Design and Synthesis of Aryl Ether Inhibitors of the *Bacillus Anthracis* Enoyl–ACP Reductase

Suresh K. Tipparaju[a,d], **Debbie C. Mulhearn**[b,d], **Gary M. Klein**[a,b], **Yufeng Chen**[a], **Subhasish Tapadar**[a], **Molly H. Bishop**[b], **Shuo Yang**[b], **Juan Chen**[c], **Mahmood Ghassemi**[c], **Bernard D. Santarsiero**[b], **James L. Cook**[c], **Mary Johlfs**[b], **Andrew D. Mesecar**[*,a,b], **Michael E. Johnson**[*,b], and **Alan P. Kozikowski**[*,a]

[a] Dr. S. K. Tipparaju, Dr. Y. Chen, Dr. S. Tapadar, Prof. Dr. A. P. Kozikowski, Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 S. Wood St., Chicago, IL 60612, USA Fax: (312) 413 0577

[b] Dr. D. C. Mulhearn, G. M. Klein, M. H. Bishop, S. Yang, Dr. B. D. Santarsiero, Dr. M. Johlfs, Dr. A. D. Mesecar, Prof. Dr. M. E. Johnson, Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 S. Ashland Ave., Chicago, IL 60607–7173, USA, Fax: (312) 413 9303

[c] Dr. J. Chen, Dr. M. Ghassemi, Dr. J. L. Cook, Department of Medicine, University of Illinois at Chicago, 808 S. Wood St., Chicago IL 60612, USA

Abstract

The problem of increasing bacterial resistance to the current generation of antibiotics is well documented. This includes such pathogens as methicillin–resistant *Staphylococcus aureus* and the potential for developing drug–resistant pathogens for use as bioweapons, such as *Bacillus anthracis*. The biphenyl ether, antibacterial triclosan exhibits broad–spectrum activity and provides a potential scaffold for the development of new, broad–spectrum antibiotics targeting the fatty acid biosynthetic pathway, *via* inhibition of enoyl–acyl carrier protein reductase (ENR). We have utilized a structure–based approach to develop novel aryl ether analogs of triclosan that target ENR, the product of the FabI gene, from *Bacillus anthracis* (*Ba*ENR). Structure–based design methods were used for the expansion of the compound series including X-ray crystal structure determination, molecular docking, and QSAR methods. Structural modifications were made to both phenyl rings of the 2-phenoxyphenyl core. A number of compounds were derived that exhibited improved potency against *Ba*ENR and increased efficacy against both the Sterne strain of *B. anthracis* and the methicillin–resistant strain of *S. aureus*. X-ray crystal structures of *Ba*ENR in complex with triclosan and two other compounds help explain the improved efficacy of the new compounds and suggest future rounds of optimisation that might be used to improve their potency.

Keywords

Triclosan; Enoyl-Reductase; Inhibitors; B. anthracis; Structure-activity relationships

Introduction

The increasing prevalence of antibiotic resistance of certain bacteria is well–documented. The 2004 monograph by the Infectious Diseases Society of America noted that the incidence

E-mail: kozikowa@uic.edu, E-mail: mesecar@uic.edu, mjohnson@uic.edu.
[d]These authors contributed equally to the preparation of this paper.

of methicillin–resistant *Staphylococcus aureus* (MRSA) in particular, has increased quite rapidly over the last two decades.[1] Recent summaries have documented that *staphylococci* are among the most common causes of nosocomial infections and that resistance to beta–lactams and glycopeptides is complicating treatment of those infections.[2] Particularly alarming is a recent JAMA article and accompanying editorial, which noted that deaths from invasive MRSA in 2005 were comparable to, or exceeded those from HIV/AIDS.[3,4] This rapid increase in bacterial resistance to current antibiotics is a strong motivation for the development of new antibacterials with alternate modes of action.

Drug resistance is also an issue for pathogens that might be used as bioweapons. For instance, the literature indicates that natural isolates of *B. anthracis* exist that are resistant to the following antibiotics: penicillin G, amoxicillin, erythromycin, cefuroxime, sulfamethoxazole, trimethoprim, cefotaxime–sodium, aztreonam and deftazidime[5–8] and ofloxacin,[9] as well as tetracycline and penicillin.[10] Further, two reports have shown that it is feasible to select for strains of *B. anthracis* that are resistant to all of the common antibiotics through standard microbial selection procedures.[11,12] Thus, whereas the 2001 bioterrorism attacks used a *B. anthracis* strain that was susceptible to conventional antibiotics, it must be considered possible that future repeats of such attacks could involve *B. anthracis* strains selected for resistance to one or more conventional antibiotics. Since anthrax has been rated first or second in potential bioterrorism impact, comparable to smallpox,[13,14] and since anthrax can be readily adapted to biowarfare applications,[14] there is incentive for the development of antibiotics with novel modes of action that could be used to combat such potential drug–resistant biothreats.[15]

To develop new antibiotics we have considered targeting of the fatty acid biosynthesis pathways, as these pathways are essential for bacterial growth and they represent validated targets for antibiotic development for several reasons.[16,17] Fatty acids are synthesized by mammals (FAS I) and bacteria (FAS II) *via* substantially different biosynthetic mechanisms, thus providing the possibility of bacteria–specific drug targeting. FAS I involves a single multifunctional enzyme–acyl carrier protein (ACP) complex, whereas FAS II utilizes several small monofunctional enzymes that operate in conjunction with ACP–associated substrates. [18] Recent studies have revealed that the genes responsible for FAS II are essential in *Bacillus subtilis*, a close relative of *B. anthracis*.[19]

Enoyl–ACP reductase (ENR), the product of the FabI gene in *Bacillus anthracis* (*Ba*ENR), is an NADH–dependent, key enzyme in FAS II that catalyzes the final and rate–determining step of chain elongation.[20] Considerable research over the past few years has shown that enoyl–ACP reductase in a number of pathogens is efficiently inhibited by antibacterial agents including isoniazid,[21] diazaboranes,[22–24] triclosan,[25–28] and several other small molecule inhibitors.[29–35] API-1252, a recently developed FabI inhibitor shows excellent *in vitro* activity against clinical isolates of *Staphylococcus epidermidis* and *Staphylococcus aureus*.[36a] Another novel FabI inhibitor, CG400462, was recently reported to show efficacy against *Staphylococcus aureus* infected mice.[36b] These studies clearly indicate that inhibition of enoyl–ACP reductase is a viable approach to develop new antibacterials with novel modes of action.

Triclosan, a 2-phenoxyphenol, is a well–known, broad–spectrum antibacterial that is used in a number of consumer products, such as toothpastes, soaps and plastics. It has been shown to inhibit the growth of *Escherichia coli*,[26,37] *Pseudomonas aeruginosa*,[38] and *Staphylococcus aureus*.[32] Originally, it was believed that triclosan was a non-specific antibacterial that attacks bacterial cell membranes. Later it was shown to have a specific mode of action that involves inhibition of bacterial fatty acid synthesis at the enoyl–acyl carrier protein reductase step.[39,40] Triclosan has since been shown to inhibit ENR from

the genes of FabI, FabL and InhA in a number of microorganisms, which has lead to several attempts to develop new triclosan derived antibacterials.[26,41–45] Improvements in the broad–spectrum activity of triclosan–like compounds have been deterred by the variability of effectiveness of triclosan against different species. For example, the IC_{50} values range from 70 nM and 73 nM respectively in *S. aurues*[32] and malaria (*Pf*ENR)[42] to only 7.25 μM in *E. coli*.[26,37] Due to this large range in activity, we believed that it would be valuable to explore the inhibitory action of additional triclosan–like aryl ether analogs against individual organisms, to maximize the specificity for each organism. Initially focusing on *B. anthracis*, we have determined the IC_{50} of triclosan against *Ba*ENR to be 0.6 μM with a MIC of 3.1 μg/mL.[46] In the current report, we describe our approaches to improve its efficacy through structural modifications to the 2-phenoxyphenol core utilizing a structure–based design approach that relies on our crystal structure of *Ba*ENR with triclosan bound in the active site.[46] Additional *Ba*ENR crystal structures involving newly designed diphenyl ethers are also presented and discussed. We find that at least two compounds exhibit improved activity against both the ΔANR and Sterne strain of *B. anthracis* as well as methicillin–resistant *Staphylococcus aureus*. The ΔANR strain of *B. anthracis* is used for the enzymatic assays as it has both the pXO1 (toxin) and pXO2 (capsule) removed. The Sterne strain of *B. anthracis* is used in subsequent antibacterial testing as it contains the pXO1 toxin but not the pXO2.

Results and Discussion

Synthesis of the inhibitors

The general synthesis of 2-phenoxyphenol core involved preparation of the corresponding methoxy substituted aryl ethers, made from commercially available materials *via* nucleophilic aromatic substitution reaction (Method A) or through Cu catalyzed coupling reactions (Methods B and C)[47] followed by demethylation of the methoxy group. Method A (Scheme 1) involves the reaction of an appropriate phenol with a fluoro–aromatic compound in the presence of K_2CO_3 and was used to prepare a variety of 2-phenoxyphenol derivatives bearing an electron withdrawing group on the ring B, namely NO_2, or CN groups (**4–6**, **8–12**, and **14**) *via* the intermediates **4a–6a**, **8a–12a**, **14a**. Compound **14** was synthesized by alkaline hydrolysis of the intermediate benzonitrile **14a** in refluxing ethanol. [48] The benzylic alcohol **16** was prepared by sodium borohydride reduction of the acid **14** in the presence of $BF_3 \cdot Et_2O$.[49] An attempt to demethylate the methoxy derivative **13b** using excess boron tribromide resulted in the formation of brominated analog **13** as a major product. Carboxamides **15** and **17** were prepared by the hydrolysis of the corresponding benzonitriles in alkaline medium containing hydrogen peroxide. [48]

Anilines **20** and **21** were synthesized *via* catalytic hydrogenation followed by demethylation of nitro intermediates **4a** and **8a** respectively (Scheme 2). The aniline intermediates **19a** and **20a** were converted to the corresponding acetamides (**19** and **18**, respectively) by reacting with acetic anhydride followed by demethylation of the methoxy derivatives. Similarly, sulfonamide **22** was prepared by treating **20a** with 4-toluenesulfonyl chloride followed by demethylation using excess boron tribromide.

Method B involves Cu catalyzed coupling reaction of an appropriate phenol with a variety of aromatic halides under thermal conditions. This method is versatile, and was used to synthesize electron rich diphenyl ethers **1**, **3**, and **7** *via* corresponding intermediates **1a**, **3a**, and **7a** respectively (Scheme 1). Heteroaromatic ring B analogs (**23–25**) were prepared by following similar protocol starting from commercially available materials (Scheme 3).

Method C is a mild copper promoted C–O coupling reaction of arylboronic acids and phenols (Schemes 4–7) that was employed to synthesize a variety of aryl ethers. This

coupling reaction complements nucleophilic aromatic substitutions (Method A) and Ullman type couplings (Method B) described above for the synthesis of aryl ethers. Although this reaction worked well with *meta-* and *para-*substituted phenylboronic acids, coupling of 2-methoxyphenols with *ortho* substituted phenylboronic acids, as well as with heteroaromatic boronic acids failed, presumably due to steric hindrance.

In Scheme 4, coupling of phenylboronic acid with eugenol and vanillin yields respective diphenyl ether intermediates **27a** and **28a** in high yields. Allyl and aldehyde functional groups were tolerated under these mild reaction conditions. The allyl group was further elaborated to the vicinal diol **26** *via* dihydroxylation and demethylation. Subjecting the allyl group to catalytic hydrogenation followed by demethylation of the resulting methoxy substituted diaryl ether resulted in the compound **27**. The aldehyde group from vanillin was either reduced to an alcohol, or transformed to a series of alkyl amines by reductive amination reactions. Thus, compounds **28** and **29**–**31** were obtained after subsequent demethylation of the corresponding methoxy substituted diaryl ethers using boron tribromide.

Scheme 5 illustrates the coupling of 2-methoxy-4-chlorophenol or 2-methoxy-4-propylphenol with commercially available *meta-* and *para-*substituted phenyldiboronic acids. While the coupling of *meta-*substituted phenyldiboronic acid and phenols resulted in high yields, *para-*substituted phenyldiboronic acid did not react very well (less than 10% yield). The intermediate triphenyl ethers **32a**–**35a** were demethylated to give compounds **32**–**35**.

Schemes 6 and 7 illustrate the synthetic routes to *meta-* and *para-*substituted ring B diphenyl ether analogs from commercially available boronic acids. The reaction works equally well for arylboronic acids bearing electron donating as well as electron withdrawing functional groups. The functional groups on the resulting diphenyl ethers were further elaborated to obtain diverse substitutions on the ring B.

Schemes 6 illustrates the synthesis of compounds **36**–**38**, **40**, and **41** *via* coupling of 2-methoxy-4-propylphenol with appropriate arylboronic acids, and subsequent demethylation of the corresponding methoxy diphenyl ethers using boron tribromide. Benzoic acid **39** was obtained by hydrolysis of the corresponding methyl benzoate **37** and compound **42** was obtained by the reduction of the ketone **40** using sodium borohydride. The methylthioether group in **41a** was oxidized by *m*-CPBA to afford methyl sulfoxide (**43a**) and methyl sulfone (**44a**), these were demthylated to afford compounds **43** and **44**, respectively. The allylic intermediates **45a** and **46a** were prepared by coupling eugenol with corresponding arylboronic acids. Reduction of the allylic side chain *via* catalytic hydrogenation, and subsequent demethylation led to compounds **45** and **46**.

In Scheme 7, 2-methoxy-4-propylphenol was coupled with 3-formylphenylboronic acid to give the aldehyde **47a**. The intermediate **47a** was converted to compound **47** *via* demethylation reaction using boron tribromide. The *meta-*aldehyde group in **47a** was subjected to Wittig reaction, and two–carbon elongated side chain analogs **48**–**51** were obtained by following similar hydrogenation and hydrolysis protocols.

Initial assay results indicate that triclosan is very effective in the inhibition of *Ba*ENR and has good antibacterial activity against *B. anthracis* (Table 1). We conducted structure–activity relationship studies on a number of aryl ether derivatives to explore the possibility of further improvement of potency of this lead compound, with the goal of optimising the activity against *Ba*ENR. The first structural modifications were directed at ring A of triclosan. As expected, the hydrogen bonding interaction of the phenolic hydroxyl group on ring A is critical for *Ba*ENR inhibitory activity. Conversion of the phenolic hydroxyl group

to ethers resulted in complete loss of activity (**52** and **53**). Attempts to replace the hydroxyl group by an amino functionality (compound **54**), carboxylic acid (compound **14**), or a carboxamide (compound **17**) resulted in no inhibition at 1μM concentrations. Replacing the phenolic hydroxyl group with an elongated hydroxy-methyl group (compound **16**) gave no improvement in activity.

Evaluation of the active site—The X-ray structure of triclosan bound to *Ba*ENR that was recently reported by us,[46] helps explain the lack of activity for this set of compounds. The binding geometry of the triclosan, shown in Figure 1A, is similar to that seen in the structures from other organisms. The phenolic 'ring A' of triclosan binds face-to-face with the nicotinamide ring of NAD$^+$ involving in a $\pi - \pi$ stacking interaction. The hydroxyl group on ring A is involved in two hydrogen bonds, one with Tyr 157 (OH) and the other with the $2'$-hydroxyl group of nicotinamide ribose. Thus, removal of these hydrogen bonds *via* alternate substitutions at the 2–position would be expected to have a substantial impact on the binding energy of these compounds with the active site and is borne out by the experimental results (Table 1). The ether linkage is also within hydrogen bonding distance to the $2'$-hydroxyl group of nicotinamide ribose, thereby adding increased binding energy between *Ba*ENR and the NAD$^+$–triclosan complex. Based on these findings, our design efforts focused on 2-phenoxyphenol as the key starting scaffold, and on finding optimal substituents for rings A and B that could maximize the van der Waals, electrostatic, and hydrogen bonding interactions in the active site of *Ba*ENR.

Connolly surface maps with various properties were generated for the active site of *Ba*ENR, see Figure 2A–C. Connolly surfaces allow the van der Waals space to be shown. Figure 2A maps the charge distribution to the surface, Figure 2B maps the lipophilicity and Figure 2C maps the hydrogen bonding opportunities found on the active site surface. Full evaluation and consideration of these active site surface maps contribute significantly to the structure–based design approach. For this system, the shape of the active site indicates that the *para* position on ring A and the *meta* and/or *para* positions on ring B, are suitable sites for introducing bulky substitutions. Further analysis of the ring A pocket indicates that it is an essentially neutral region in terms of charge (Figure 2A), and that there is also a lack of hydrogen bonding opportunities (Figure 2C). The lipophilicity map in Figure 2B suggests the ring A pocket to be dominated by a high amount of hydrophobicity. Thus, we focused our attention on substitutions that could add hydrophobic interactions within the ring A pocket.

Substitutions on Ring A—We limited modifications of ring A to the *para*-substituent, R^1, due to steric constraints observed in the crystal structure of triclosan bound to *Ba*ENR. Compound **55**,[37] bereft of substituents on ring B, was earlier shown to be a potent inhibitor of ENR from *E. Coli*. Compound **55** shows activity similar to that of triclosan against *Ba*ENR (Table 1), although its MIC value against ΔANR *B. anthracis* is an order of magnitude lower. To reveal the true effect on binding affinities of the different substitutions, compound **55** was used as a reference for comparison of activities among this set of compounds. Replacement of the chlorine atom located at the R^1 position on ring A with polar hydrophilic functionalities such as OH and NO$_2$ decreased the inhibitory activity against *Ba*ENR (compounds **1** and **2**, Table 1). Although compound **2** has a reasonable antibacterial activity (MIC = 5.8 μg/mL), its poor enzyme inhibitory activity suggests that it may be working through some other mechanism. Because of poor solubilities of many of these diphenyl ether derivatives, we were forced to introduce polar hydrophilic groups at the R^1 position. Unfortunately, this resulted in compounds with lower inhibitory activity (compounds **26**, **28**, and **29**–**31**, Table 1). The design of compounds in this investigation was

also based on comparision of calculated molecular properties (CLogP, ALOGpS and TPSA) with those of triclosan.[50]

The weaker inhibitions of compounds with polar side chains at the R^1 position is in agreement with the surface–map property analysis of the active site from the *Ba*ENR–triclosan X-ray structure (Figures 2A–2C). The surface maps show the importance of the hydrophobic pocket, which is approximately 6 Å in diameter near the *para* position of ring A. Moreover, the maps explain the experimental results whereby there are no opportunities for additional hydrogen bonds to occur within the ring A pocket. From the crystal structure shown in Figure 1, it is clear that hydrophobic residues dominate the region surrounding ring A. Sullivan et al. recently reported potent inhibition of ENR (InhA) from *Mycobacterium tuberculosis* by triclosan analogs bearing long aliphatic chains at the R^1 position.[43,51] Since the ring A pocket in *Ba*ENR is much smaller than in the InhA, numerous aliphatic chain lengths (2–8 carbons) were evaluated *via* GOLD docking prior to synthesis, to optimise the chain length for our active site. We are confident that the GOLD docking can accurately predict the binding conformation of these diphenyl ether analogs. An overlay of the GOLD docking conformation of triclosan with the crystal structure is seen in Figure 1A, and shows it to be in very good agreement (RMSD = 0.32 Å). Compound **27**, possessing an *n*-propyl group was suggested by the docking result (conformation and scoring) to be the best prospect, thus it was synthesized and tested. Compound **27** turned out to have an IC_{50} value higher than compound **55** as judged by the fact that it could not saturate the *Ba*ENR active site under the experimental concentrations attempted. These compounds had sparing solubility so it was difficult to accurately quantitate IC_{50} values. However, compound **27** had an MIC value similar to that of compound **55**, so we chose to expand upon two series of compounds. The first was based on a chloro group at R^1 of ring A (compound **55**), and the second was based on the *n*-propyl group at R^1 (compound **27**).

Substitutions on Ring B—In our preliminary search to identify the optimum substitutions on ring B, the first series of modifications to this ring were made while retaining ring A as the starting 2-hydroxy-4-chlorophenyl moiety. The goal was to improve the affinity of these compounds for *Ba*ENR by increasing the hydrogen bonding to the protein residues in the ring B pocket, specifically to the backbone residues in the region of Ala 95–Ala 97. These residues were judged to be potential hydrogen bond donors/acceptors based on the modeling and crystal structure analysis presented in Figures 1 and 2. Thus, we introduced several functional groups at the 4′-position of ring B that have the potential to form hydrogen bonds. Compound **55**, with an IC_{50} of 0.5 μM and an MIC of 32 μg/mL was our reference material for comparing the activities of this set of structures. Introduction of a hydroxyl group at the *para* position on ring B did not improve the activity (compound **3**, Table 2). Compound **20**, bearing an amino group, showed improved antibacterial activity, but its IC_{50} against *Ba*ENR was only 7 μM. Further acetylation or sulfonylation of the amino group was not effective in improving the *Ba*ENR activity (compounds **18**, **19**, and **22**).

Compound **6**, possessing *ortho*-chloro and *para*-nitro groups on ring B, proved to be the best inhibitor in this series (IC_{50} = 290 nM, and MIC = 3.1 μg/mL). This compound has earlier been shown to be active against the malarial ENR from *P. falciparum*.[41] The presence of a nitro group not only adds a strong electron withdrawing group to ring B, but perhaps more importantly, it adds two potential hydrogen bond acceptor atoms close to the aromatic ring. Compound **7**, with a 4′-phenyl group, is more active against the bacterium (MIC = 1.9 μg/mL) than triclosan, but it is not as effective against *Ba*ENR, indicating that its action may be non-specific or that the biphenyl ring improves bacterial membrane penetration. Similarly, the symmetrical triaryl ethers **32** and **33** were ineffective against *Ba*ENR, even though **33** showed improved antibacterial activity.

Considerable improvement in the IC$_{50}$ values of compound **6** over **4** (less than 20% inhibition at 1 μM) suggests that the 2′-chloro group contributes considerably to the affinity of these compounds. From the crystal structure of triclosan bound to *Ba*ENR (see Figure 1A), the 2′-chloro is 2.6 Å from the side chain hydroxyl of Ser 197 which is in favourable position for a halogen–oxygen interaction. [52] The Ser 197 (OH) is also 2.7 Å from one of the oxygen atoms of the bridging phosphate group of NAD$^+$. It is possible that the improved activity of the compounds possessing a 2′-chloro group is due to this hydrogen–bonding network, rendering ring B in a 'locked' orientation thereby positioning *para* substituents optimally to form hydrogen bonds with the backbone of Ala 97. Hydrogen–bonding to Ser 197 (OH) may also stabilize positioning of the substrate binding or "flipping" loop, which is documented as being flexible in a number of organisms. [16,17,46]

To potentially improve the solubility of these diphenyl ethers, we synthesized and studied the activity of derivatives bearing a heteroaromatic ring as ring B, such as the pyridine and pyrazine analogs of **55** (data shown in supplemental material). These compounds failed to show promising activity. Compound **24**, containing an acetamidopyridine ring, gave a moderate IC$_{50}$ value (IC$_{50}$ = 4.1 μM), but proved to be inactive against the bacterium (MIC > 111.5 μg/mL). Therefore, introduction of a heteroatom into ring B of these aryl ether analogs was ineffective, and further pursuit of such modifications was terminated.

Having established a preliminary SAR at this stage, we set out to combine our knowledge obtained from our study of the ring A and B modifications, in order to produce compounds of optimal activity. We therefore synthesized compounds whereby ring A is fixed with the more hydrophobic 2-hydroxy-4-*n*-propylphenyl moiety (Compound **27**, Table 1) and ring B is modified with various substituents that provide additional hydrogen bond donors and/or acceptor atoms, both at the *meta* and the *para* positions of ring B. The goal once again was to design compounds to interact with the residues in the region of Ala 97, positioning the ring B substituents toward the entrance of the active site, closer to the protein surface.

Table 3 shows the results from the *n*-propyl series of compounds. Overall, an improvement in both the IC$_{50}$ and MIC values were found over the values listed in Tables 1 and 2. Introduction of small, hydrophilic hydrogen–bond acceptor groups that have the ability to withdraw electron density from the aromatic ring B produces improved activity. The best results were obtained when ring B contained a nitro or a cyano substituent (compounds **8**, **9**, **10**–**12**, Table 3). In line with the results obtained in Table 2 discussed above, the presence of a 2′-chloro group contributed to the binding affinity of these inhibitors (compound **8** *vs* **11**). Compounds with either an amide or methyl ketone group also had inhibitory activity similar to that of triclosan (compounds **15** and **40**). The compounds with an electron rich amino group at the *para* position were found to be weak inhibitors of *Ba*ENR (e.g., compare compound **8** *vs* **21**), consistent with the results of compound **55** *vs* **20** (Table 2).

The correlation of inhibitory activities of compounds according to the electron donating *vs* withdrawing ability of functional groups such as NH$_2$ *vs* NO$_2$ at the *para* position of ring B, does not hold for the sulfur containing substituent groups. Improved IC$_{50}$ values were seen with the more electron donating methylthioether group (**41**, IC$_{50}$ = 0.6 μM), while compounds bearing relatively stronger electron withdrawing groups (a methylsulfoxide in **43**, IC$_{50}$ = 3.6 μM or the methylsulfone in **44**, IC$_{50}$ = 2.2 μM) were only moderately active. It appears that, along with an electrostatic effect, a steric contribution and/or orientation of the hydrogen bonding acceptor group in the active site is contributing to the inhibitory activity of these compounds. Since the geometry around the sulfur atom of a sulfone is not the same as the geometry around the nitrogen atom of a nitro group, the two oxygens attached to the sulfur or nitrogen would be positioned very differently, and could result in varied hydrogen bonding capabilities. It is notable here that methyl ketone **40**, which is a

close structural analog of methylsulfoxide **43**, exhibits improved inhibitory activity against *Ba*ENR and ΔANR *B. anthracis* (IC$_{50}$ = 0.8 μM, MIC = 13.5 μg/mL).

To better understand the binding interactions of these inhibitors at the active site, we determined the X-ray crystal structures of inhibitors **11** and **43** bound to *Ba*ENR in the presence of NAD$^+$, both at resolutions of 2.3 Å (see Figures 1B and 1C), and compared them to the structure of *Ba*ENR in complex with triclosan. As expected from modeling, the binding geometries of these inhibitors were nearly identical to that of triclosan. The most significant difference between the structures was the interaction of the ring B *para* substituent and the residues in the enzyme. Improved activity of compound **11** could be attributed to the 'additional' hydrogen bonding occurring between the *para* nitro group of **11** and Ala 97(NH) (~2.2 Å). GOLD docking accurately predicted the orientation of this nitro group, as well as the proposed orientation of the 2′-Cl group within hydrogen bonding distance to the sidechain of Ser 197. Figure 1B is an overlay of X-ray crystal structure of compound **11** and its GOLD docking conformation in the active site of *Ba*ENR (RMSD = 0.45 Å). Figure 1C is an overlay of X-ray crystal structure of compound **43** and its GOLD docking conformation in the active site of *Ba*ENR (RMSD = 0.69 Å). As in compound **11**, (Figure 1B), there is very good agreement between the two, as well as the correct prediction of the sulfoxide's oxygen hydrogen bonding to Ala 97(NH) (~1.8 Å).

Ring B modifications at the *meta* position involved the addition of heteroatoms very close to the aromatic ring. This included compounds **45** (NMe$_2$), **46** (CF$_3$), and **38** (CH$_2$OH). Of these, only compound **46** showed improved activities against *Ba*ENR and the bacterium. Compounds **36** and **34**, with a *meta*-phenyl group substitution on ring B, were more active toward the bacterium than triclosan itself (MIC = 1.9 and 1.2 μg/mL respectively), but exhibited lower activity against the *Ba*ENR enzyme. It is well documented that the ENR from multiple organisms has a very flexible substrate binding loop.[46, 53] It is possible that the above compounds with larger groups induce a shift in this flexible substrate–binding loop, opening up the active site. This would likely lead to a decrease in the binding of the ligand and possibly result in lower affinity of the compound for *Ba*ENR.

Compounds **37**–**39**, and **48**–**51** are closely related ester/acid analogs chemically extended from the *meta*-position of ring B. As previously noted, modeling and structural analysis suggests that opportunities for hydrogen bonding between substituents on ring B and the active site residues exists in the region of the Ala 97 on *Ba*ENR. The best opportunities for this hydrogen bonding to occur are with the hydrogen bonding group being located approximately 1–2 atoms away from ring B, as seen in compounds **37**–**39**. Similar hydrogen bonding opportunities are not as likely for the longer chain substituents found in **48**–**51**, and results in weaker inhibition. Although this extension proved disappointing, these results do indicate that the acids were less inhibitory than esters toward the *Ba*ENR enzyme (**37** *vs* **39**, **49** *vs* **51**).

Overall, the assay results indicated that a few of the *meta* substituted analogs in Table 3 show IC$_{50}$ values near 1μM, with the majority having little activity against *Ba*ENR (less than 20% inhibition at 1 μM). This is in contrast to the *para* substituted analogs, which in general had IC$_{50}$ values less than 3.6 μM. Antibacterial activity for this series in Table 3 suggested that the *meta* compounds have better MICs than similar *para* derivatives (compare compounds **34** and **35**). Figure 3 summarizes the SAR of the diphenyl ethers studied, showing the key pharmacophoric elements required for effective *Ba*ENR inhibition.

Regardless of antibacterial activity, the *n*-propyl series of compounds show better inhibitory activity against *Ba*ENR than the chloro series shown in Table 2. More importantly, this series has resulted in nine compounds (**8**, **9**, **11**, **12**, **15**, **27**, **36**, **40**, and **41**) that are

equipotent or nearly equipotent with triclosan. Of these, **15**, **40**, and **41** have potential for future structural modification and expansion. Pressence of a chloro group at the 2′-position on ring B has shown to increase activity against *Ba*ENR. Interestingly, we observed a similar improvement in the binding affinity of 2-pyridone derivatives to the *Ba*ENR active site in a recent study.[54] Thus, introduction of a chloro group to **40** and **41** is likely to be beneficial in improving the activity of these inhibitors. Additionally, compounds **15**, **40**, and **41** ideally possess functional groups at the *para* position of ring B, a carboxamide in **15**, a methyl ketone in **40**, and a thioether in **41** that are useful in the design of the next generation of compounds.

CoMFA Maps and future design implications—Even though GOLD did a good job at predicting the binding conformations of simple substitutions, it is unable to account for the flexibility in the *Ba*ENR's substrate binding loop. To aid in future design, we turned to a ligand–based approach, a 3D–QSAR, or CoMFA. We generated a CoMFA for our results against *Ba*ENR presented in Tables 1–3 and Supplemental Material. The CoMFA model has a $q^2 = 0.831$ and an $r^2 = 0.929$. Figure 2D shows the steric and electrostatic fields generated from the CoMFA. One can see the favorability of a negative charge around the 2-hydroxy position of ring A (red regions), as well as at the *para* position of ring B. Sterically, the CoMFA map suggests expansion to be concentrated at the *meta/para* position of the ring B. Expansions on ring A should be limited, as shown by the yellow regions here. One potential misleading region is the large green region behind the molecule. From the crystal structure, we know this to be the region where NAD^+ binds, and modifications to the structure in these regions are not likely to be beneficial since the binding of triclosan and analogs relies on the co–binding of the product, NAD^+, for maximal binding energy.[37,46,55] The CoMFA model visually illustrates sites for future structural expansion of these aryl ether compounds, and will be used for further predictions of activity for the next generation of compounds.

Antibacterial testing of lead compounds—Table 4 shows the MICs and MBCs of two of our *Ba*ENR inhibitors, **6** and **11**, against several bacterial pathogens. The broth microdilution method of the National Committee for Laboratory Standards was validated using a panel of ATCC strains of bacterial pathogens with known MICs to ciprofloxacin. This method was employed for the MIC and MBC determinations for these two inhibitors. From the results, these two compounds are equally active and bactericidal against Sterne and ΔANR strains of *B. anthracis*. These compounds also have noticeable activity against both Gram (+) and Gram (−) bacterial pathogens, suggesting that these types of compounds could be expanded for a more broad–spectrum application. The notable exception is the high–level resistance of *Pseudomonas aeruginosa,* which has been reported for triclosan,[56] and may be explained by bacterial efflux pump activity.[29] Of particular note is the impressive activity against MRSA, with an MIC = 0.3 μg/mL for both compounds and an MBC/MIC ratio of 1.6–1.9, compared with a ratio of approximately 20 for the tested strain of methicillin–sensitive *S. aureus* (MSSA). The observation of comparable MICs for MRSA and MSSA is consistent with previous comparisons of large numbers of both types of *S. aureus* isolates.[56] If the 10–fold increase in bactericidal activity against MRSA *vs.* MSSA is reproducible upon testing multiple strains of each, it might be interesting to pursue mechanistically. Previous studies have indicated that the bactericidal activity of triclosan against *S. aureus* isolates (both MRSA and MSSA) may be unrelated to MIC and might involve multiple bacterial targets of such compounds.[57] It is likely that compounds **6** and **11** target FabI in *S. aureus* too. In the absence of a reported X-ray crystal structure of ENR from *S. aureus*, explanation of increased activity should rely upon secondary structures. Sequence alignment of the ENR from *S. aureus* with *B. anthracis* indicates a 62% identity, with all residues in the substrate–binding loop (residues 190–210) completely conserved. In addition, all the residues within 5 Å radius of the ENR active site are conserved in both *S.*

aureus and *B. anthracis*. The only exception being a Met 99 present in *S. aureus* ENR, this position is occupied by Arg 99 in *Ba*ENR. The location of the Arg 99 in *B. anthracis* is near the surface of ENR, where the arginine side chain partially covers the entrance to the active site. Presence of a methionine in its place in *S. aureus* ENR is likely to leave the active site more accessible for the ligands, and could partially explain the increased activity found against *S. aureus* for these types of compounds, as compared with *B. anthracis*. Therefore, further study will be needed to assess the possible strain specificity and ENR pathway relatedness of these MBC/MIC findings. A preliminary cytotoxicity testing for compounds **6** and **11** (see footnote in Table 4) showed an EC_{50}/MIC ratio of approximately 15–20 for both compounds against HeLa cells. Further testing is needed to validate these values, and whether structural modifications are necessary to minimize toxicity.

Conclusion

A number of novel aryl ethers, including triphenyl ethers and heteroaromatic analogs have been prepared and tested for inhibition of purified *Ba*ENR and cultured ΔANR *Bacillus anthracis*. These efforts have led to an improved understanding of the enzyme active site and provided a clear SAR for these inhibitors. The X-ray crystal structures, coupled with molecular modeling studies, have demonstrated the importance of hydrophobic interactions of substituents located at the *para* position on ring A with the enzyme active site and underscore the H–bonding contribution of the *ortho* and *para* substituents on ring B with Ser 197 (OH) and Ala 97. The importance of the *ortho*-chloro group on ring B for the improvement of activity warrants further investigation. These results highlight the subtleness of an appropriate electronic distribution in either of the aromatic rings of the 2-phenoxyphenol core to allow for optimal interaction with the active site. For example, although incorporation of an *n*-propyl group in place of the chlorine atom at the *para*-position of ring A was advantageous in improving the effectiveness of the inhibitors, this should also be simultaneously complemented with an appropriate substitution pattern on ring B. We are continuing our structure–based design efforts, with newer efforts focused on modifications at the *para* position of ring B, with linking groups such as thioethers, amides, and esters, as well as modification of the nitro group.

Several compounds have been synthesized that exhibit varied structural diversity, show improved antibacterial activity over triclosan, and offer an opportunity to identify new inhibitory pathways and drug candidates. The encouraging inhibitory activities of these compounds against a number of pathogens suggest their potential for broad–spectrum application. The intriguing activity shown by compounds **6** and **11** against methicillin–resistant *S. aureus* provides potential leads against a serious and increasingly common pathogen. To advance these compounds further, pharmacokinetic and drug metabolism studies are planned.

Experimental Section

General

^1H NMR and ^{13}C NMR spectra were recorded on Bruker spectrometer with TMS as an internal standard. Standard abbreviation indicating multiplicity was used as follows: s = singlet, d = doublet, t = triplet, q = quadruplet, quin = quintuplet, m = multiplet and br = broad. HRMS experiment was performed on Q–TOF–2TM (Micromass). The progress of all reactions was monitored by TLC on precoated *silica gel* plates (Merck *Silica Gel* 60 F254). Preparative TLC was performed with Analtech 1000–mm *silica gel* GF plates. Column chromatography was performed using Merck *silica gel* (40 –60 mesh). HPLC was carried out on an ACE AQ columns (100 × 4.6 mm and 250 × 10 mm), with detection at 254 nm on a Shimadzu SPD–10A VP detector; flow rate = 2.0–3.5 mL·min^{-1}; from 10% acetonitrile in

water to 100% acetonitrile with 0.05% TFA. Compound **54** is commercially available. Compounds **53**, **55**,[37] and **28**[26,37] are known in the literature.

Synthesis of inhibitors

General Methods—Method A. The aryl halide (1 mmol), phenol (1 mmol), and K$_2$CO$_3$ (2–4 mmol) in DMSO (1.5 mL) were heated to 100 °C under nitrogen until the reaction was shown to be complete by TLC (8–12 h). After cooling to rt, the reaction mixture was diluted with ethyl acetate, and washed with 5% aqueous NaOH solution. The aqueous layer was further extracted with ethyl acetate, and the combined organic layers were washed with brine. The organic layer was dried over Na$_2$SO$_4$, and concentrated under vacuum to give the crude product, which was subsequently purified by flash chromatography on *silica gel*. **Method B.** To the phenol (1 mmol) dissolved in DMF (1.75 mL) was added KO*t*Bu (1.1 mmol) in one portion and the mixture was heated at 45 °C under mild vacuum. After 2 h, the reaction mixture was cooled to rt. Aryl halide (1 mmol) and (CuOTf)$_2$·PhH (0.05 mmol) were added and the mixture was heated to reflux at 145 °C for 16–20 h. After cooling to rt, the reaction mixture was diluted with ethyl acetate, filtered over Celite, and extracted with ethyl acetate. The extract was washed with 5% aqueous NaOH solution. The aqueous layer was then extracted with ethyl acetate, and the combined organic layers were washed with brine. The organic layer was dried over Na$_2$SO$_4$, and concentrated under vacuum to give the crude product, which was subsequently purified by flash chromatography on *silica gel*. **Method C.** The arylboronic acid (1–2 mmol), phenol (1 mmol), Cu(OAc)$_2$ (2–5 mmol), triethyl amine (5–10 mmol), and powdered 5 Å molecular sieves were mixed in dichloromethane (10 mL), and were stirred in the presence of atmospheric air until the reaction was shown to be complete by TLC (3–16 h). The reaction mixture was diluted with ethyl acetate, filtered over Celite, and extracted. The extract was washed with 5% aqueous NaOH solution. The aqueous layer was further extracted with ethyl acetate, and the combined organic layers were washed with brine. The organic layer was dried over Na$_2$SO$_4$, and concentrated under vacuum to give the crude product, which was subsequently purified by flash chromatography on *silica gel*. **Method D.** In each case, the methoxy diarylether derivatives obtained by the above methods were converted to the corresponding phenols using boron tribromide according to the following procedure: A solution of boron tribromide (2–8 mmol of 1.0 M solution in dichloromethane) was added to a solution of the corresponding methoxy diphenylether analog (1 mmol) in dry dichloromethane (4 mL) maintained at −78 °C under nitrogen. The reaction mixture was stirred at the same temperature (1 h), and then at rt (3–8 h) while monitoring by TLC. Following completion, the reaction was quenched with methanol at −78 °C and concentrated under vacuum. The concentrate was further dissolved in ethyl acetate, washed with 10% aqueous sodium bicarbonate solution, and the organic layer was separated and washed with water and then with brine. The aqueous layer was extracted twice with ethyl acetate. The combined organic layers were then dried over Na$_2$SO$_4$, concentrated under vacuum, and the crude product was purified by flash chromatography on *silica gel*.

4-Phenoxybenzene-1,3-diol (1)

Method B was used to prepare the intermediate **1a** from 2,4-dimethoxyphenol (1.00 g, 6.5 mmol), KO*t*Bu (0.87 g, 7.8 mmol), (CuOTf)$_2$·PhH (0.17 g, 0.3 mmol) and iodobenzene (1.59 g, 7.8 mmol) in 50% yield, and method D was used to convert it to the title compound. Purification by flash chromatography (SiO$_2$, 10% EtOAc/Hexanes) gave analytically pure **1** as viscous brown oil (80%). ^{1}H NMR (400 MHz, CDCl$_3$): δ = 4.86 (s, 1H), 5.56 (s, 1H), 6.36 (dd, J = 9.0, J = 3.0 Hz, 1H), 6.58 (d, J = 2.8 Hz, 1H), 6.83 (d, J = 8.7 Hz, 1H), 7.08 (d, J = 7.6 Hz, 2H), 7.09 (t, J = 7.4 Hz, 1H), 7.33 ppm (t, J = 7.4 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 103.4, 107.3, 116.4, 120.6, 122.7, 129.5, 136.3, 148.0, 152.5, 157.3 ppm; HRMS (ESI-positive): calcd for C$_{12}$H$_{10}$O$_3$ ([M−H]$^+$): 201.0557, found: 201.0556.

5-Nitro-2-phenoxyphenol (2)

Method A was used to prepare the methoxy intermediate **2a** from phenol (0.66 g, 7.0 mmol), commercially available 1-fluoro-2-methoxy-4-nitrobenzene (1.12 g, 7.0 mmol) and K_2CO_3 (1.80 g, 12.8 mmol) in 48% yield, and method D was used to convert it to the title compound. Purification by flash chromatography (SiO_2, 15% EtOAc/Hexanes) gave the analytically pure product **2** as a greenish yellow oil (75%). ^1H NMR (400 MHz, CDCl$_3$): δ = 6.53 (br s, 1H), 7.08–7.14 (m, 3H), 7.26 (t, J = 7.6 Hz, 1H), 7.43 (t, J = 7.6 Hz, 2H), 7.70 (d, J = 2.8 Hz, 1H), 7.97 ppm (dd, J = 4.0, J = 2.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 112.5, 115.3, 118.8, 120.1, 124.9, 130.0, 140.7, 143.9, 154.5, 152.4 ppm; HRMS (ESI-positive): calcd for $C_{12}H_9NO_4$ ([M–H]$^+$): 230.0459, found: 230.0458.

5-Chloro-2-(4-hydroxyphenoxy)phenol (3)

Method B was used to prepare the dimethoxy intermediate **3a** from 4-chloro-2-methoxyphenol (1.00 g, 6.3 mmol), KOtBu (0.85 g, 7.6 mmol), (CuOTf)$_2$·PhH (0.17 g, 0.3 mmol), and 4-iodoanisole (1.80 g, 7.6 mmol) in 49% yield, and method D was used to convert it to the phenol **3**. Purification by flash chromatography (10% EtOAc/Hexanes) gave the analytically pure product as a colourless oil (82%). ^1H NMR (400 MHz, CDCl$_3$): δ = 4.68 (s, 1H), 5.72 (s, 1H), 6.70 (d, J = 8.8 Hz, 1H), 6.79 (dd, J = 8.0, J = 2.0 Hz, 1H), 6.84 (dd, J = 7.0, J = 2.0 Hz, 2H), 6.94 (dd, J = 7.0, J = 2.0 Hz, 2H), 7.04 ppm (d, J = 2.4 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 115.8, 116.1, 117.4, 119.8, 119.9, 128.2, 143.3, 147.1, 149.1, 151.7 ppm; HRMS (ESI-positive): calcd for $C_{12}H_9ClO_3$ ([M–H]$^+$): 235.0168, found: 235.0166.

5-Chloro-2-(4-nitrophenoxy)phenol (4)

Method A was used to prepare the methoxy intermediate **4a** in 96% yield, as described in the synthesis of **20**. Method D was used to convert it to the required phenol **4**. Purification by flash chromatography (3% MeOH/CHCl$_3$) gave the analytically pure product as a muddy brown solid (70%). ^1H NMR (400 MHz, CDCl$_3$): δ = 5.42 (s, 1H), 6.95 (s, 2H), 7.14–7.02 (m, 3H), 8.26 ppm (d, J = 9.2 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 116.5, 117.3, 120.9, 121.1, 125.7, 131.2, 139.7, 142.9, 147.9, 161.7 ppm; HRMS (ESI-positive): calcd for $C_{12}H_8ClNO_4$ ([M–H]$^+$): 264.0069, found: 264.0069.

5-Chloro-2-(2-nitrophenoxy)phenol (5)

Method A was used to prepare the methoxy intermediate **5a** in 96% yield, as described in the synthesis of **19**, and method D was used to convert it to the phenol **5**. Purification by flash chromatography (1% MeOH/CHCl$_3$) gave the analytically pure product as an off white solid (76%). ^1H NMR (400 MHz, CDCl$_3$): δ = 6.89 (dd, J = 4.0, J = 2.0 Hz, 1H), 6.98 (d, J = 4.0 Hz, 1H), 7.12–7.08 (m, 2H), 7.28–7.23 (m, 1H), 7.57–7.53 (m, 1H), 7.94 ppm (dd, J = 4.0, J = 1.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 117.8, 118.9, 120.6, 121.3, 123.9, 125.9, 131.5, 134.6, 140.9, 148.7, 150.0 ppm; HRMS (ESI-positive): calcd for $C_{12}H_8ClNO_4$ ([M–H]$^+$): 264.0069, found: 264.0068.

5-Chloro-2-(2-chloro-4-nitrophenoxy)phenol (6)

Method A was used to prepare the corresponding methoxy intermediate **6a** in 91% yield from 4-chloro-2-methoxyphenol (1.00 g, 6.3 mmol), 2-chloro-1-fluoro-4-nitrobenzene (1.10 g, 6.3 mmol), and K_2CO_3 (1.80 g, 12.6 mmol) by heating the mixture in DMSO (10 mL) at 100 °C (12 h). Method D was used to convert it to the target compound. Purification by flash chromatography (3% MeOH/CHCl$_3$) gave the analytically pure product **6** as a light yellow solid (79%). ^1H NMR (400 MHz, CDCl$_3$): δ = 5.73 (s, 1H), 6.97–6.91(m, 3H), 7.14 (d, J = 1.2 Hz, 1H), 8.11 (dd, J = 4.0, J = 1.0 Hz, 1H), 8.41 ppm (d, J = 2.0 Hz, 1H); ^{13}C NMR (400 MHz, CDCl$_3$): δ = 116.1, 117.5, 120.8, 121.0, 123.4, 124.2, 126.3, 131.5, 139.7,

142.9, 147.7, 157.4 ppm; HRMS (ESI-positive): calcd for $C_{12}H_7Cl_2NO_4$ ([M−H]$^+$): 297.9679, found: 297.9679.

2-(Biphenyl-4-yloxy)-5-chlorophenol (7)

Method B was used to prepare the methoxy intermediate **7a** from 4-chloro-2-methoxyphenol (1.00 g, 6.3 mmol), KO*t*Bu (0.78 g, 6.9 mmol), (CuOTf)$_2$·PhH (0.16 g, 0.3 mmol), and 4-bromobiphenyl (1.47 g, 6.3 mmol) in 69% yield, and method D was used to convert it to the phenol **7**. Purification by flash chromatography (2% EtOAc/Hexanes) gave the analytically pure product as a white solid (65%). ^{1}H NMR (400 MHz, CDCl$_3$): δ = 5.83 (br s, 1H), 6.90 (s, 2H), 7.12 (d, *J* = 8.8 Hz, 3H), 7.40 (t, *J* = 7.2 Hz, 1H), 7.49 (t, *J* = 7.2 Hz, 2H), 7.61 ppm (d, *J* = 8.0 Hz, 4H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 116.3, 117.9, 119.1, 120.3, 126.6, 126.9, 128.3, 128.5, 129.39, 129.2, 136.8, 139.8, 142.9, 147.7, 155.5 ppm; HRMS (ESI-positive): calcd for $C_{18}H_{13}ClO_2$ ([M+H]$^+$): 297.0621, found: 297.0652.

2-(4-Nitrophenoxy)-5-propylphenol (8)

Method A was used to prepare the methoxy intermediate **8a** in 93% yield from 2-methoxy-4-propylphenol (1.00 g, 6.3 mmol), 1-fluoro-4-nitrobenzene (0.89 g, 6.3 mmol) and K$_2$CO$_3$ (1.80 g, 12.6 mmol) by heating the mixture in DMSO (10 mL) at 100 °C (12 h), and method D was used to convert it to the title compound. Purification by flash chromatography (10% EtOAc/Hexanes) gave the analytically pure product **8** as an yellow solid (96%). ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.99 (t, *J* = 3.2 Hz, 3H), 1.65 (q, *J* = 3.6 Hz, 2H), 2.59 (t, *J* = 3.6 Hz, 2H), 6.77 (d, *J* = 8.0 Hz, 1H), 6.90–6.91 (m, 2H), 7.07 (d, *J* = 9.2 Hz, 2H), 8.21 ppm (d, *J* = 1.2 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.4, 23.9, 37.2, 116.1, 116.8, 120.3, 120.9, 125.6, 138.6, 141.5, 146.9, 162.5 ppm; HRMS (ESI-positive): calcd for $C_{15}H_{15}NO_4$ ([M−H]$^+$): 272.0928, found: 272.0925.

2-(3-Nitrophenoxy)-5-propylphenol (9)

Method A was used to prepare the methoxy precursor **9a** in 65% yield from 2-methoxy-4-propylphenol (1.00 g, 6.3 mmol), 1-fluoro-3-nitrobenzene (0.89 g, 6.3 mmol) and K$_2$CO$_3$ (1.8 g, 12.6 mmol) by heating the mixture in DMSO (10 mL) at 100 °C (10 h), and method D was used to convert it to the title compound. Purification by flash chromatography (15% EtOAc/Hexanes) gave the analytically pure product **9** as an yellow solid (83%). ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.99 (t, *J* = 7.2 Hz, 3H), 1.67 (quin, *J* = 7.6 Hz, 2H), 2.59 (t, *J* = 7.6 Hz, 2H), 5.37 (s, 1H), 6.76 (dd, *J* = 4.0, *J* = 2.0 Hz, 1H), 6.89 (d, *J* = 8.0 Hz, 1H), 6.93 (d, *J* = 1.6 Hz, 1H), 7.36 (dd, *J* = 5.0, *J* = 2.0 Hz, 1H), 7.50 (t, *J* = 8.2 Hz, 1H), 7.83 (t, *J* = 2.0 Hz, 1H), 7.96 ppm (dd, *J* = 4.0, *J* = 1.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.4, 23.9, 37.1, 111.5, 116.7, 117.3, 119.6, 120.8, 122.7, 129.9, 139.2, 141.0, 146.9, 148.8, 157.9 ppm; HRMS (ESI-positive): calcd for $C_{15}H_{15}NO_4$ ([M−H]$^+$): 272.0928, found: 272.0926.

2-(2,4-Dinitrophenoxy)-5-propylphenol (10)

Method A was used to prepare the methoxy precursor **10a** in 93% yield from 2-methoxy-4-propylphenol (0.50 g, 3.0 mmol), 1-fluoro-2,4-dinitrobenzene (0.56 g, 3.0 mmol), and K$_2$CO$_3$ (0.84 g, 6.0 mmol) by heating the mixture in DMSO (10 mL) at 100 °C (8 h), and method D was used to convert it to the title compound. Purification by flash chromatography (10% EtOAc/Hexanes) gave the analytically pure product **10** (81%). ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.95 (t, *J* = 7.2 Hz, 3H), 1.65 (quin, *J* = 7.2 Hz, 2H), 2.59 (t, *J* = 7.2 Hz, 2H), 5.72 (s, 1H), 6.83 (d, *J* = 8.2 Hz, 1H), 7.02 (s, 1H), 7.06–7.04 (m, 1H), 7.18–7.13 (m, 1H), 8.36 (dd, *J* = 4.0, *J* = 3.0 Hz, 1H), 8.84 ppm (t, *J* = 2.8 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$) δ = 13.3, 24.0, 36.9, 117.4, 117.5, 120.8, 121.2, 121.6, 127.6, 128.7, 136.2, 137.8, 141.2, 142.9, 144.8, 146.8, 155.4 ppm; HRMS (ESI-positive): calcd for $C_{15}H_{14}N_2O_6$ ([M−H]$^+$): 317.0779, found: 317.0776.

2-(2-Chloro-4-nitrophenoxy)-5-propylphenol (11)

Method A was used to prepare the methoxy intermediate **11a** in 93% yield from 2-methoxy-4-propylphenol (0.50 g, 3.0 mmol), 2-chloro-1-fluoro-4-nitrobenzene (0.53 g, 3.0 mmol), and K_2CO_3 (0.84 g, 6.1 mmol) by heating the mixture in DMSO (10 mL) at 100 °C (12 h), and method D was used to convert it to the title compound. Purification by flash chromatography (10% EtOAc/Hexanes) gave the analytically pure product **11** (82%). ^{1}H NMR (400 MHz, $CDCl_3$): δ = 0.97 (t, J = 7.2 Hz, 3H), 1.66 (quin, J = 7.6 Hz, 2H), 2.57 (t, J = 7.6 Hz, 2H), 5.55 (s, 1H), 6.77 (dd, J = 4.0, J = 2.0 Hz, 1H), 6.91–6.89 (m, 3H), 8.02 (dd, J = 5.0, J = 2.0 Hz, 1H), 8.33 ppm (d, J = 2.0 Hz, 1H); ^{13}C NMR (100 MHz, $CDCl_3$): δ = 13.4, 23.9, 37.1, 115.3, 117.1, 120.2, 121.1, 123.3, 123.5, 125.9, 138.5, 141.9, 142.1, 146.7, 158.3 ppm; HRMS (ESI-positive): calcd for $C_{15}H_{14}ClNO_4$ ([M–H]+): 306.0539, found: 306.0541.

3-Chloro-4-(2-hydroxy-4-propylphenoxy)benzonitrile (12)

Method A was used to prepare the methoxy intermediate **12a** in 80% yield from 2-methoxy-4-propylphenol (1.00 g, 6.3 mmol), 3-chloro-4-fluorobenzonitrile (0.94 g, 6.0 mmol), and K_2CO_3 (1.7 g, 12.0 mmol) by heating the mixture in DMSO (20 mL) at 100 °C (14 h), and method D was used to convert it to the target compound. Purification by flash chromatography (10% EtOAc/Hexanes) gave the analytically pure product **12** (79%). ^{1}H NMR (400 MHz, $CDCl_3$): δ = 7.76 (d, J = 2.0 Hz, 1H), 7.47 (dd, J = 4.0, J = 2.0 Hz, 1H), 6.93–6.87 (m, 3H), 6.78–6.75 (m, 1H), 5.42 (s, 1H), 2.58 (t, J = 7.6 Hz, 2H), 1.67 (quin, J = 7.6 Hz, 2H), 0.98 (t, J = 7.2 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$): δ = 13.4, 23.9, 37.1, 106.3, 116.4, 117.0, 120.1, 120.9, 124.1, 131.8, 133.8, 138.5, 141.7, 146.9, 156.9 ppm; HRMS (ESI-positive): calcd for $C_{16}H_{14}ClNO_2$ ([M–H]+): 286.0640, found: 286.0637.

2-[3-(2-Hydroxy-ethyl)phenoxy]-5-propylphenol (13)

Method B was used to prepare the methoxy-vinyl compound **13a** from the appropriate phenol, and 3-bromostyrene (62%). This methoxy-vinyl compound **13a** was subjected to hydroboration/alkaline hydrolysis, wherein it was treated with 1 M borane tetrahydrofuran complex in anhydrous tetrahydrofuran (0.5 equivalents), and the mixture was stirred at rt (3 h). Aqueous 3M NaOH solution (7 mL) followed by 30% hydrogen peroxide (4 mL) were added slowly drop wise to the above reaction mixture at 0 °C, and stirring continued (12 h) at rt. Usual workup followed by purification using flash column chromatography (2% MeOH/$CHCl_3$) resulted in the methoxy compound **13b** (68%). Method D was used to convert this methoxy precursor to **13**. Purification by flash chrom atography (5% EtOAc/Hexanes) gave the analytically pure product as a colorless oil (75%). ^{1}H NMR (400 MHz, $CDCl_3$): δ = 0.98 (t, J = 7.2 Hz, 3H), 1.67 (t, J = 7.6 Hz, 2H), 2.57 (t, J = 7.6 Hz, 2H), 3.16 (t, J = 7.6 Hz, 2H), 3.57 (t, J = 7.2 Hz, 2H), 5.47 (s, 1H), 6.69 (dd, J = 4.0 Hz, J = 2.0 Hz, 1H), 6.84 (d, J = 8.4 Hz, 1H), 6.93–6.89 (m, 3H), 6.97 (d, J = 7.2 Hz, 1H), 7.30 ppm (t, J = 7.2 Hz, 1H); ^{13}C NMR (100 MHz, $CDCl_3$): δ = 13.9, 24.5, 32.6, 37.6, 39.1, 116.0, 116.3, 117.8, 119.1, 120.7, 123.6, 129.9, 140.0, 140.9, 141.0, 147.3, 157.5 ppm; HRMS (ESI-positive): calcd for $C_{17}H_{19}BrO_2$ ([M–H]+): 333.0496, found: 333.0492.

5-Chloro-2-phenoxybenzoic acid (14)

Method A was used to prepare the intermediate nitrile **14a**. 5-chloro-2-fluorobenzonitrile (1.00 g, 6.4 mmol), phenol (0.66 g, 7.0 mmol) and K_2CO_3 (1.8 g, 12.8 mmol) were mixed in anhydrous DMSO (10 mL), and heated at 100 °C (8 h). A mixture of this nitrile **14a** (0.20 g, 0.9 mmol) and 25% aqueous NaOH (0.4 mL) in ethanol (2 mL) was refluxed with stirring (20 h). After cooling, the reaction mixture was acidified with dilute hydrochloric acid. The precipitate was filtered, dried, and purified by column chromatography (SiO_2, 6% MeOH/$CHCl_3$) to yield the title compound (143 mg, 64%) as a white solid. ^{1}H NMR (400 MHz,

CD$_3$OD): δ = 6.95 (m, 3H), 7.1 (t, J = 8.0 Hz, 1H), 7.33 (t, J = 8.0 Hz, 2H), 7.46 (dd, J = 9.0, J = 3.0 Hz, 1H), 7.84 ppm (d, J = 2.0 Hz, 1H); ^{13}C NMR (100 MHz, CD$_3$OD): δ = 119.6, 123.1, 124.8, 129.6, 131.1, 132.4, 134.4, 156.5, 158.6 ppm; MS (ESI) m/z: 249 [M + H]$^+$; HRMS (ESI-positive): calcd for C$_{13}$H$_9$ClO$_3$Na ([M + Na]$^+$): 271.0133, found: 271.0129.

3-Chloro-4-(2-hydroxy-4-propylphenoxy)benzamide (15)

A mixture of nitrile **12** (0.38 g, 1.3 mmol), 30% hydrogen peroxide (1 mL), and aqueous 3N NaOH (0.18 mL) in ethanol was stirred at 35 °C (20 h). The resulting mixture was acidified with 1N sulfuric acid. Ethanol was evaporated in vacuum, and the white precipitate was dissolved in ethyl acetate, and washed with water followed by brine. Evaporation of the solvent resulted in the crude product which was purified by flash chromatography (3% MeOH/CHCl$_3$) to give analytically pure product **15** as a white solid (65%). ^{1}H NMR (400 MHz, CD$_3$OD): δ = 0.91 (t, J = 7.6 Hz, 3H), 1.58 (quin, J = 7.6 Hz, 2H), 2.50 (t, J = 7.6 Hz, 2H), 6.62 (d, J = 8.0 Hz, 1H), 6.68 (dd, J = 4.0, J = 2.0 Hz, 1H), 6.82 (d, J = 2.0 Hz, 1H), 6.95 (d, J = 8.0 Hz, 1H), 7.39 (br s, 1H), 7.73 (dd, J = 4.0, J = 2.0 Hz, 1H), 7.97 (br s, 1H), 8.03 ppm (d, J = 2.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 115.5, 117.7, 120.2, 121.5, 122.3, 128.3, 129.1, 129.9, 139.7, 141.1, 149.1, 156.3, 166.6 ppm; HRMS (ESI-positive): calcd for C$_{16}$H$_{16}$ClNO$_3$ ([M−H]$^+$): 304.0746, found: 304.0743.

5-Chloro-2-phenoxyphenylmethanol (16)

A solution of BF$_3$·Et$_2$O (17 μL, 0.13 mmol) in THF (2 mL) was slowly added to a mixture of NaBH$_4$ (0.012 g, 0.31 mmol) and the acid **14** (0.051 g, 0.21 mmol) in THF (1 mL) at rt under an inert atmosphere. The mixture was heated to reflux (1 h). The reaction mixture was cooled to 0 °C, and quenched with water. After 10 min, THF was removed under reduced pressure, CH$_2$Cl$_2$ was added, and the stirring was continued (1 h). The organic layer was separated, washed with brine, dried over anhydrous Na$_2$SO$_4$, and solvent was removed under reduced pressure. Purification of the crude residue by column chromatography (18% EtOAc/Hexanes) afforded the title compound **16** (39 mg, 80%) as a white solid. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 2.11 (br s, 1H), 4.72 (s, 2H), 6.79 (d, J = 9.0 Hz, 1H), 6.96 (d, J = 8.0 Hz, 2H), 7.12 (t, J = 8.0 Hz, 1 H), 7.20 (dd, J = 8.0, J = 2.0 Hz, 1H), 7.34 (t, J = 8.0 Hz, 2H), 7.47 ppm (d, J = 3.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 60.7, 118.6, 119.9, 123.4, 129.0, 129.1, 130.2, 133.9, 153.3, 157.0 ppm; MS (ESI) m/z: 217 [M − H$_2$O + H]$^+$.

5-Chloro-2-phenoxybenzamide (17)

A mixture of the intermediate nitrile **14a** (0.20 g, 0.9 mmol), 35% hydrogen peroxide (0.37 mL) and 3N aqueous NaOH (0.36 mL) in ethanol (5 mL) was stirred at 30 °C (18 h). The resulting mixture was acidified with 1N sulphuric acid, the precipitate was filtered, dried and purified by column chromatography (60% EtOAc/Hexanes) to afford the title compound **17** (171 mg, 70%) as a white solid. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 6.55 (br s, 1H), 6.76 (d, J = 8.0 Hz, 1H), 7.07 (d, J = 6.0 Hz, 2H), 7.26 (t, J = 8.0 Hz, 1H), 7.34 (dd, J = 9.0, J = 3.0 Hz, 1H), 7.42 (t, J = 8.0 Hz, 2H), 7.55 (br s, 1H), 8.24 ppm (d, J = 2.0 Hz, 1H). ^{13}C NMR (100 MHz, CDCl$_3$): δ = 119.6, 120.0, 125.4, 129.2, 130.6, 132.4, 133.2, 154.9, 133.2, 165.0 ppm; MS (ESI) m/z: 248 [M+H]$^+$; HRMS (ESI-positive): calcd for C$_{13}$H$_{10}$ClNO$_2$Na ([M + Na]$^+$): 270.0293, found 270.0286.

N-[4-(4-Chloro-2-hydroxy-phenoxy)phenyl]acetamide (18)

The corresponding methoxy intermediate **20a** (0.14 g, 0.6 mmol), prepared as described in the synthesis of **20**, was acetylated by treating with acetic anhydride (0.07 g, 0.7 mmol), catalytic DMAP and Et$_3$N (0.07 g, 0.7 mmol) in methylene chloride (2 mL) at 0 °C (3h). Method D was used to convert it to the target compound. Purification by flash

chromatography (3% MeOH/CHCl$_3$) gave the analytically pure product **18** as a white solid (92%). ^{1}H NMR (400 MHz, CD$_3$OD): δ = 2.11 (s, 3H), 7.00–6.78 (m, 5H), 7.52–7.45 ppm (m, 2H); ^{13}C NMR (400 MHz, CD$_3$OD): δ = 21.9, 116.4, 116.9, 119.0, 120.6, 121.2, 121.3, 124.2, 128.6, 133.1, 142.6, 149.2, 153.6, 169.8 ppm; HRMS (ESI-positive): calcd for C$_{14}$H$_{12}$ClNO$_3$ ([M–H]$^+$): 276.0433, found: 276.0432.

N-[2-(4-Chloro-2-hydroxy-phenoxy)phenyl]acetamide (19)

Method A was used to prepare the methoxy intermediate **5a**, from 4-chloro-2-methoxyphenol (1.00 g, 6.3 mmol), 1-fluoro-2-nitrobenzene (0.89 g, 6.3 mmol), and K$_2$CO$_3$ (1.80 g, 12.6 mmol) in 96% yield. A mixture of **5a** (1.70 g, 6.1 mmol), 10% Pd/C (0.30 mg), and EtOH (24 mL) was stirred at rt under H$_2$ atmosphere. After 6 h, the reaction mixture was filtered through Celite, and the filter pad was washed with EtOH. The filtrate was concentrated in *vacuo*. The residue was purified by flash chromatography on *silica gel* (10% EtOAc/Hexane) to give the amino intermediate **19a** (0.82 g, 92%) as a brown liquid. This intermediate **19a** was acetylated by treating with acetic anhydride, catalytic DMAP and Et$_3$N in methylene chloride at 0 °C in 3h. Method D was used to convert it to the target compound. Purification by flash chromatography (3% MeOH/CHCl$_3$) gave the analytically pure product **19** as a white solid (92%). ^{1}H NMR (400 MHz, CD$_3$OD): δ = 2.17 (s, 3H), 6.73 (dd, J = 4.0, J = 1 Hz, 1H), 6.84 (dd, J = 4.0, J = 2.0 Hz, 1H), 6.98–6.93 (m, 2H), 7.09–7.03 (m, 2H), 7.76 ppm (dd, J = 3.0, J = 1 Hz, 1H); ^{13}C NMR (100 MHz, CD$_3$OD): δ = 21.7, 115.1, 116.7, 119.1, 121.7, 122.2, 123.8, 125.1, 127.1, 129.5, 141.5, 149.0, 149.3, 170.3 ppm; HRMS (ESI-positive): calcd for C$_{14}$H$_{12}$ClNO$_3$ ([M–H]$^+$): 276.0433, found: 276.0429.

2-(4-Aminophenoxy)-5-chlorophenol (20)

Method A was used to prepare the methoxy intermediate **4a**, from 4-chloro-2-methoxyphenol (1.00 g, 6.3 mmol), 1-fluoro-4-nitrobenzene (0.89 g, 6.3 mmol), and K$_2$CO$_3$ (1.8 g, 12.6 mmol) in 96% yield. A mixture of **4a** (1.00 g, 3.6 mmol), 10% Pd/C (0.36 g), and EtOH (20 mL) was stirred at rt under H$_2$ atmosphere. After 4 h, the reaction mixture was filtered through Celite, and the filter pad was washed with MeOH. The filtrate was concentrated in *vacuo*. The residue was purified by flash chromatography on *silica gel* (20% EtOAc/Hexanes) to give the amino intermediate **20a** (0.82 g, 92%) as a brown liquid. Method D was used to convert this amino intermediate **20a** to the required compound **20**. Purification by flash chromatography (20% EtOAc/Hexanes) gave the analytically pure product as brown solid (82%). ^{1}H NMR (400 MHz, (CD$_3$)$_2$SO): δ = 4.89 (br s, 2H), 6.54 (d, J = 8.8 Hz, 2H), 6.67 (d, J = 8.8 Hz, 2H), 6.74 (dd, J = 4.0, J = 2.0 Hz, 2H), 6.90 ppm (d, J = 2.4 Hz, 2H); ^{13}C NMR (100 MHz, CD$_3$OD): δ = 115.3, 116.9, 119.3, 119.5, 119.7, 119.9, 126.8, 145.2, 145.5, 147.3, 149.5 ppm; HRMS (ESI-positive): calcd for C$_{12}$H$_{10}$ClNO$_2$ ([M +H]$^+$): 236.0473, found: 236.0471.

2-(4-Aminophenoxy)-5-propylphenol (21)

Method A was used to prepare the methoxy intermediate **8a** in 93% yield from 2-methoxy-4-propylphenol (1.00 g, 6.3 mmol), 1-fluoro-4-nitrobenzene (0.89 g, 6.3 mmol), and K$_2$CO$_3$ (1.80 g, 12.6 mmol) by heating the mixture in DMSO (10 mL) at 100 °C (12 h). A mixture of **8a** (1.00 g, 3.6 mmol), 10% Pd/C (0.36 g), and MeOH (20 mL) was stirred at rt under H$_2$ atmosphere. After 4 h, the reaction mixture was filtered through Celite, and the filter pad was washed with MeOH. The filtrate was concentrated in *vacuo*. The residue was purified by flash chromatography on *silica gel* (20% EtOAc/Hexanes) to give the amino intermediate **21a** (0.82 g, 92%) as a brown liquid. Method D was used to convert the intermediate **21a** to the title compound. Purification by flash chromatography (3% MeOH/CHCl$_3$) gave the analytically pure product **21** (84%). ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.96

(t, J = 7.6 Hz, 3H), 1.65 (quin, J = 7.6 Hz, 2H), 2.53 (t, J = 7.6 Hz, 2H), 6.62 (d, J = 8.0 Hz, 1H), 6.71–6.67 (m, 3H), 6.89–6.87 ppm (m, 3H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.4, 24.1, 37.1, 115.3, 115.9, 116.6, 119.4, 119.8, 138.1, 142.1, 142.5, 146.2, 148.6 ppm; HRMS (ESI-positive): calcd for C$_{15}$H$_{17}$NO$_2$ ([M–H]$^+$): 242.1236, found: 242.1238.

4-(4-Chloro-2-hydroxyphenoxy)-1-(4 methylphenylsulphonamido) benzene (22)

Amino intermediate **20a** (0.16 g, 0.63 mmol) was dissolved in anhydrous methylene chloride (3 mL), and cooled to 0 °C and then triethylamine (0.2 mL, 1.25 mmol) was added, after 10 minutes, tosyl chloride (0.18 g, 0.94 mmol) was added, and the reaction mixture was stirred at the rt (3 h). The reaction was quenched by adding 10 mL of 1M HCl, and diluted with ethyl acetate (100 mL), the organic layer was separated, and the aqueous layer was extracted twice with ethyl acetate. All the organic layers were combined and washed with water, brine, and dried over anhydrous Na$_2$SO$_4$, and concentrated in *vacuo*. The crude reaction mixture was subjected to subsequent reaction without further purification. General method D was applied for demethylation. Purification of the crude reaction mixture by column chromatography (22% EtOAc/Hexanes) afforded the title compound **22** (122 mg, 50%) as a white solid. ^{1}H NMR (300 MHz, CDCl$_3$): δ = 2.41 (s, 3H), 5.66 (s, 1H), 6.68 (s, 1H), 6.72 (d, J = 9.0 Hz, 1H), 6.81 (dd, J = 9.0, J = 2.0 Hz, 1H), 6.90 (m, 2H), 7.04 (m, 3H), 7.26 (d, J = 8.0 Hz, 2H), 7.64 ppm (d, J = 9.0 Hz, 2H); ^{13}C NMR (75 MHz, CDCl$_3$): δ = 21.8, 116.9, 118.9, 119.6, 120.8, 124.7, 127.5, 129.9, 136.2, 142.3, 144.2, 154.5 ppm; MS (ESI) *m/z*: 412 [M + Na]$^+$. HRMS (ESI-positive): calcd for C$_{19}$H$_{15}$ClNO$_4$S ([M–H]$^+$): 388.0416, found 388.0415.

5-Chloro-2-(pyridin-3-yloxy)phenol (23)

Method B was used to prepare the methoxy precursor 3-(4-chloro-2-methoxyphenoxy)pyridine in 48% from 4-chloro-2-methoxyphenol (1 g, 6.3 mmol), KO*t*Bu (0.85 g, 7.6 mmol), (CuOTf)$_2$·PhH (0.33 g, 0.63 mmol), and 3-iodopyridine (1.60 g, 7.6 mmol), and method D was used to convert it to the phenol **23.** Purification by flash chromatography (3% MeOH/CHCl$_3$) gave the analytically pure product as an off white solid (52%). ^{1}H NMR (400 MHz, CD$_3$OD): δ = 4.83 (s, 1H), 5.56 (s, 1H), 6.36 (dd, J = 8.0, J = 2.0 Hz, 1H), 6.58 (d, J = 2.8 Hz, 1H), 6.88 (dd, J = 4.0, J = 2.0 Hz, 1H), 7.03–6.97 (m, 2H), 7.39–7.29 (m, 2H), 8.23 ppm (br s, 2H); ^{13}C NMR (100 MHz, CD$_3$OD): δ = 116.7, 119.3, 122.2, 123.3, 124.1, 130.2, 137.8, 140.6, 141.9, 149.8 ppm; HRMS (ESI-positive): calcd for C$_{11}$H$_8$ClNO$_2$ ([M–H]$^+$): 220.0171, found: 220.0170.

N-[5-(4-Chloro-2-hydroxyphenoxy)-pyridin-2-yl]acetamide (24)

The methoxy precursor N-[5-(4-chloro-2-methoxyphenoxy)-pyridin-2-yl]acetamide was prepared from commercially available 4-chloro-2-methoxyphenol (1.00 g, 6.3 mmol), N-(5-iodo-pyridin-2-yl)acetamide (1.4 g, 5.3 mmol), KO*t*Bu (0.78 g, 7.0 mmol), and (CuOTf)$_2$·PhH (0.49 g, 0.95 mmol) using method B (15%), and method D was used to convert it to the phenol **24**. Purification by flash chrom atography (8% MeOH/CHCl$_3$) gave the analytically pure product as a white solid (60%). ^{1}H NMR (400 MHz, CDCl$_3$): δ = 2.16 (s, 3H), 6.84 (dd, J = 4.0, J = 2.0 Hz, 1H), 6.93–6.98 (m, 2H), 7.31 (dd, J = 8.0, J = 3.0 Hz, 1H), 7.98 (d, J = 2.8 Hz, 1H), 8.02 ppm (d, J = 8.9 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 114.9, 117.0, 119.6, 119.9, 120.7, 121.6, 125.4, 125.9, 126.0, 129.9, 136.6, 136.7, 142.2, 146.6, 148.9, 149.8, 151.1, 170.3 ppm; HRMS (ESI-positive): calcd for C$_{13}$H$_{11}$ClN$_2$O$_3$ ([M–H]$^+$): 277.0385, found: 277.0384.

5-Chloro-2-(pyrazin-2-yloxy)phenol (25)

Method B was used to prepare the methoxy precursor 2-(4-chloro-2-methoxyphenoxy)pyrazine in 67% yield from commercially available 4-chloro-2-

methoxyphenol (1.00 g, 6.3 mmol), 2-iodopyrazine (1.10 g, 5.3 mmol), KO*t*Bu (0.78 g, 7.0 mmol) and (CuOTf)$_2$·PhH (0.49 g, 0.95 mmol), and method D was used to convert it to the phenol **25**. Purification by flash chromatography (3% MeOH/CHCl$_3$) gave the analytically pure product as a white solid (73%). ^{1}H NMR (400 MHz, CD$_3$OD): δ = 6.88 (dd, J = 4.0, J = 3.0 Hz, 1H), 6.96 (d, J = 2.4 Hz, 1H), 7.09 (d, J = 8.8 Hz, 1H), 8.1 (dd, J = 2.0, J = 1.0 Hz, 1H), 8.25 (d, J = 2.8 Hz, 1H), 8.41 ppm (d, J = 1.6 Hz, 1H); ^{13}C NMR (100 MHz, CD$_3$OD): δ = 116.4, 117.2, 118.9, 122.5, 123.3, 125.7, 130.5, 134.4, 137.4, 137.5, 140.6 ppm; HRMS (ESI-positive): calcd for C$_{10}$H$_7$ClN$_2$O$_2$ ([M–H]$^+$): 221.0123, found: 221.0123.

3-(3-Hydroxy-4-phenoxyphenyl)propane-1,2-diol (26)

To a stirred solution of intermediate **27a** (0.10 g, 0.41 mmol) in THF (20 mL) were added *N*-methyl-morpholine *N*-oxide (0.20 g, 1.66 mmol) and a solution of 4 wt.% OsO$_4$/H$_2$O (0.24 mL, 0.038 mmol, 4 mol%) and the reaction was allowed to stir (12 h), at which time all staring material had been consumed as monitored by TLC. The reaction mixture was poured into a solution of 15% Na$_2$SO$_3$ (50 mL), extracted with CH$_2$Cl$_2$. The organic extract was washed with brine, dried with MgSO$_4$, and evaporated in *vacuo*. The crude material was subjected to subsequent demethylation according to the general procedure described in method D, to yield 31 mg (28%) of **26**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 2.75 (t, J = 7.7 Hz, 2H), 3.58–3.54 (m, 1H), 3.75–3.72 (m, 1H), 3.97 (br s, 1H), 5.47 (s, 1H), 6.68 (dd, J = 8.0, J = 1.0 Hz, 1H), 6.82 (d, J = 8.1 Hz, 1H), 5.66 (s, 1H), 6.72 (dd, J = 8.0, J = 1.0 Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H), 6.95 (s, 1H), 7.04 (d, J = 8.0 Hz, 2H), 7.14 (t, J = 7.3 Hz, 1H), 7.36 ppm (t, J = 7.8 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 39.2, 66.0, 72.8, 116.8, 117.8, 118.9, 121.3, 123.6, 129.8, 134.4, 142.1, 147.4 ppm; HRMS (ESI-positive): calcd for C$_{15}$H$_{16}$O$_4$ ([M–H]$^+$): 259.0975, found: 259.0978.

2-Phenoxy-5-propylphenol (27)

A suspension of intermediate **27a** (0.10 g, 0.41 mmol) and 10% Pd/C (0.02 g) in EtOAc was stirred under a hydrogen atmosphere at rt (4 h). The catalyst was removed by filtration through a pad of Celite, and the residue was thoroughly washed with EtOAc. The solvent was evaporated to give a crude residue, which was directly subjected to demethylation using the standard procedure described in method D above. The crude product was purified by preparative TLC (30% EtOAc/Hexanes) to afford 54 mg (71%) of **27**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.97 (t, J = 7.3 Hz, 3H), 1.69–1.62 (m, 2H), 2.56 (t, J = 7.5 Hz, 2H), 5.49 (s, 1H), 6.68 (dd, J = 8.0, J = 1.0 Hz, 1H), 6.83 (d, J = 8.2 Hz, 1H), 6.90 (d, J = 1.6 Hz, 1H), 7.03 (d, J = 7.8 Hz, 2H), 7.12 (t, J = 7.3 Hz, 1H), 7.35 ppm (t, J = 7.7 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.7, 24.4, 37.5, 116.0, 117.5, 118.9, 120.5, 123.2, 129.7, 139.8, 147.2, 141.0, 157.1 ppm.

5-Hydroxymethyl-2-phenoxyphenol (28)

A mixture of intermediate **28a** (0.08 g, 0.34 mmol), and BBr$_3$ (1M, 6.9 mL, 6.9 mmol) was subjected to the general demethylation procedure described in method D above. The crude product was purified by preparative TLC (40% EtOAc/Hexanes) to afford 64 mg (85%) of **28**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 4.48 (s, 2H), 5.66 (s, 1H), 6.82 (d, J = 7.3 Hz, 1H), 6.89 (dd, J = 8.0, J = 2.0 Hz, 1H), 7.06 (d, J = 8.3 Hz, 2H), 7.12 (d, J = 2.0 Hz, 1H), 7.17 (t, J = 7.3 Hz, 1H), 7.38 (t, J = 7.8 Hz, 2H) ppm; ^{13}C NMR (100 MHz, CDCl$_3$): δ = 33.2, 116.7, 118.2, 118.4, 121.3, 124.0, 129.9, 134.0, 143.9, 147.2, 156.1 ppm.

5-[(1-Methyl-butylamino)methyl]-2-phenoxyphenol (29)

A mixture of intermediate **29a** (0.10 g, 0.33 mmol), and BBr$_3$ (1M, 6.6 mL, 6.6 mmol) were subjected to the general demethylation procedure outlined in method D above. The crude product was purified by preparative TLC (10% MeOH/CH$_2$Cl$_2$) to afford 65 mg (68%) of

29. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.91 (t, J = 7.4 Hz, 3H), 1.09 (d, J = 11.0 Hz, 3H), 1.41–1.34 (m, 1H), 1.58–1.51 (m, 1H), 2.67–2.62 (m, 1H), 3.78–3.67 (m, 2H), 6.79–6.77 (m, 1H), 6.84 (d, J = 8.1 Hz, 1H), 6.99 (d, J = 7.9 Hz, 2H), 7.01 (d, J = 1.4 Hz, 1H), 7.10 (d, J = 7.3 Hz, 1H), 7.33 ppm t, J = 7.8 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 10.2, 19.5, 29.6, 50.7, 53.9, 116.6, 117.5, 119.2, 120.1, 123.1, 129.7, 137.4, 142.3, 147.7, 157.1, 165.0 ppm.

2-Phenoxy-5-piperidin-1-ylmethylphenol (30)

The intermediate **30a** (0.07 g, 0.23 mmol) was subjected to the general demethylation procedure outlined in method D above using 4.7 mL of 1M BBr$_3$ in dichloromethane solution. The residue was purified by preparative TLC using 1:10 MeOH/CH$_2$Cl$_2$ to afford **30** (34 mg, 50%). ^{1}H NMR (400 MHz, CDCl$_3$): δ = 1.47 (br s, 2H), 1.70–1.60 (m, 4H), 2.47 (br s, 4H), 3.49 (s, 2H), 6.83 (s, 2H), 7.03 (d, J = 7.8 Hz, 2H), 7.12 (t, J = 7.3 Hz, 1H), 7.07 (s, 1H), 7.35 ppm (t, J = 8.0 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 24.1, 25.5, 54.2, 63.0, 117.2, 117.8, 118.6, 121.4, 123.4, 129.8, 142.5, 147.3, 156.9 ppm.

5-(Benzylaminomethyl)-2-phenoxyphenol (31)

A mixture of intermediate **31a** (0.08 g, 0.25 mmol) and BBr$_3$ (1M, 5 mL, 5.0 mmol) were subjected to the general demethylation procedure outlined in method D above. The crude product was purified by preparative TLC (10% MeOH/CH$_2$Cl$_2$) to afford 42 mg (54%) of **31**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 3.78 (s, 2H), 3.86 (s, 2H), 6.84 (s, 2H), 7.00 (d, J = 8.0 Hz, 2H), 7.14–7.10 (m, 2H), 7.42–7.28 ppm (m, 7H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 51.5, 52.0, 116.6, 117.8, 119.0, 120.6, 123.4, 127.5, 128.5, 128.6, 128.7, 129.8, 134.4, 137.6, 142.9, 147.7, 156.8 ppm. HRMS (ESI-positive): calcd for C$_{20}$H$_{19}$NO$_2$ ([M−H]$^+$): 304.1343, found: 304.1352.

2-[4-(2-Hydroxy-4-Chlorophenoxy)phenoxy]-5-chlorophenol (32)

A mixture of 2-methoxy-4-propylphenol (0.20 g, 1.2 mmol), and benzene-1, 4-diboronic acid (0.20 g, 1.2 mmol) were subjected to the general biaryl ether coupling procedure described in method C. The crude product was purified by preparative TLC (30% EtOAc/Hexanes) to afford 35 mg (7%) of intermediate **32a**. A mixture of **32a** (0.03 g, 0.076 mmol) and BBr$_3$ (1M, 1.5 mL, 1.5 mmol) was subjected to the general demethylation procedure outlined above in method D. The crude product was purified by preparative TLC (40% EtOAc/Hexanes) to afford 12 mg (43%) of **32**. ^{1}H NMR (400 MHz, (CD$_3$)$_2$SO): δ = 6.86–6.83 (m, 6H), 6.93 (d, J = 7.5 Hz, 2H), 6.98 (d, J = 2.3 Hz, 2H), 10.06 ppm (s, 2H); ^{13}C NMR (100 MHz, (CD$_3$)$_2$SO): δ = 117.3, 118.3, 119.7, 122.6, 128.5, 143.1, 150.4, 152.9 ppm. HRMS (ESI-positive): calcd for C$_{18}$H$_{12}$Cl$_2$O$_4$ ([M−H]$^+$): 361.0039, found: 361.0046.

2-[3-(2-Hydroxy-4-chlorophenoxy)phenoxy]-5-chlorophenol (33)

A mixture of 2-methoxy-4-propylphenol (0.20 g, 1.20 mmol), and benzene-1, 3-diboronic acid (0.20 g, 1.20 mmol) were subjected to the general biaryl ether coupling procedure described in method C. The crude product was purified by preparative TLC (30% EtOAc/Hexanes) to afford 207 mg (41%) of intermediate **33a**. A mixture of **33a** (0.1 g, 0.25 mmol) and BBr$_3$ (1M, 5.1 mL, 5.1 mmol) was subjected to the general demethylation procedure outlined above in method D. The crude product was purified by preparative TLC (40% EtOAc/Hexanes) to afford 65 mg (70%) of **33**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.96 (t, J = 7.3 Hz, 6H), 1.70–1.60 (m, 4H), 2.55 (t, J = 7.4 Hz, 4H), 5.68 (s, 2H), 6.76–6.71 (m, 3H), 6.86 (s, 4H), 7.08 (t, J = 1.2 Hz, 2H), 7.30 ppm (t, J = 8.2 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 107.2, 111.9, 112.2, 116.4, 116.5, 119.1, 119.7, 120.4, 129.7, 130.5, 141.1, 147.7, 157.6 ppm. HRMS (ESI-positive): calcd for C$_{18}$H$_{12}$Cl$_2$O$_4$ ([M−H]$^+$): 361.0039, found: 361.0050.

2-[3-(2-Hydroxy-4-propylphenoxy)phenoxy]-5-Propylphenol (34)

A mixture of 2-methoxy-4-propylphenol (0.20 g, 1.2 mmol), and benzene-1,3-diboronic acid (0.20 g, 1.2 mmol) was subjected to the general biaryl ether coupling procedure described in method C. The crude product was purified by preparative TLC (30% EtOAc/Hexanes) to afford 27 mg (5%) of intermediate **34a**. A mixture of **34a** (0.10 g, 0.24 mmol), and BBr$_3$ (1M, 4.9 mL, 4.9 mmol) was subjected to the general demethylation procedure outlined in method D above. The crude product was purified by preparative TLC (40% EtOAc/ Hexanes) to afford 67 mg (71%) of **34**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.97 (t, J = 7.3 Hz, 6H), 1.70–1.60 (m, 4H), 2.56 (t, J = 7.4 Hz, 4H), 5.40 (s, 2H), 6.75–6.65 (m, 5H), 6.86 (s, 1H), 6.88 (t, J = 1.8 Hz, 3H), 7.27–7.22 ppm (m, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.3, 24.0, 37.1, 106.4, 111.3, 115.9, 119.0, 120.3, 130.1, 139.9, 146.8, 158.2 ppm; HRMS (ESI-positive): calcd for C$_{24}$H$_{26}$O$_4$ ([M−H]$^+$): 377.1758, found: 377.1763.

2-[4-(2-Hydroxy-4-propylphenoxy)phenoxy]-5-propylphenol (35)

A mixture of 2-methoxy-4-propylphenol (0.20 g, 1.2 mmol), and benzene-1,4-diboronic acid (0.20 g, 1.2 mmol) was subjected to the general biaryl ether coupling procedure outlined in method C above. The crude product was purified by preparative TLC (30% EtOAc/ Hexanes) to afford 27 mg (5%) of **35a**. A mixture of **35a** (0.02 g, 0.049 mmol), and BBr$_3$ (1M, 0.98 mL, 0.98 mmol) was subjected to the general demethylation procedure outlined above. The crude product was purified by preparative TLC (40% EtOAc/Hexanes) to afford 13 mg (69%) of **35**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.96 (t, J = 7.3 Hz, 6H), 1.70–1.60 (m, 4H), 2.55 (t, J = 7.4 Hz, 4H), 5.51 (s, 2H), 6.67 (dd, J = 8.0, J = 2.0 Hz, 2H), 6.79 (d, J = 8.2 Hz, 2H), 6.89 (d, J = 1.8 Hz, 2H), 7.00 ppm (s, 4H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.3, 24.0, 37.1, 115.6, 117.8, 118.7, 120.1, 139.2, 141.1, 146.5, 152.3 ppm; HRMS (ESI-positive): calcd for C$_{26}$H$_{26}$O$_5$ ([M−H]$^+$): 377.1758, found: 377.1747.

2-(Biphenyl-3-yloxy)-5-propylphenol (36)

A mixture of 4-propyl-2-methoxyphenol (0.10 g, 0.6 mmol), and 3-biphenylboronic acid (0.36 g, 1.8 mmol) was subjected to the general biaryl ether coupling procedure outlined in the method C above to obtain intermediate **36a** in 46% yield. A mixture of **36a** (0.08 g, 0.25 mmol), and BBr$_3$ (1M, 5.0 mL, 5.0 mmol) was subjected to the general demethylation procedure described in method D above. The crude product was purified by preparative TLC (40% EtOAc/Hexanes) to afford 34 mg (44%) of **36**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.99 (t, J = 7.3 Hz, 3H), 1.75–1.65 (m, 2H), 2.58 (t, J = 7.4 Hz, 2H), 5.56 (s, 1H), 6.71 (d, J = 8.2 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 6.93 (s, 1H), 7.01 (d, J = 6.7 Hz, 1H), 7.42–7.35 (m, 3H), 7.46 (t, J = 7.3 Hz, 2H), 7.59 ppm (d, J = 7.4 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.4, 24.0, 37.1, 115.7, 115.9, 116.0, 118.6, 120.2, 121.7, 126.7, 127.2, 128.4, 129.7, 139.5, 139.9, 140.6, 142.8, 146.8, 157.2 ppm; HRMS (ESI-positive): calcd for C$_{29}$H$_{34}$N$_4$O$_5$ ([M−H]$^+$): 519.2602, found: 519.2595.

3-(2-Hydroxy-4-propylphenoxy)benzoic acid methyl ester (37)

A mixture of 4-propyl-2-methoxyphenol (0.10 g, 0.6 mmol), and 3-(ethoxycarbonyl) phenylboronic acid (0.32 g, 1.8 mmol) was subjected to the general biaryl ether coupling procedure outlined in method C above to obtain intermediate **37a** in 41% yield. A mixture of **37a** (0.07 g, 0.23 mmol) and BBr$_3$ (1M, 4.6 mL, 4.6 mmol) was subjected to the general demethylation procedure described in method D. The crude product was purified by preparative TLC (50% EtOAc/Hexanes) to afford 44 mg (65%) of **37**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.97 (t, J = 7.3 Hz, 3H), 1.69–1.62 (m, 2H), 2.57 (t, J = 7.5 Hz, 2H), 3.91 (s, 3H), 5.56 (s, 1H), 6.72 (dd, J = 8.0, J = 2.0 Hz, 1H), 6.82 (d, J = 8.2 Hz, 1H), 6.91 (d, J = 1.8 Hz, 1H), 7.22–7.19 (m, 1H), 7.40 (t, J = 8.0 Hz, 1H), 7.68–7.67 (m, 1H), 7.77 ppm (d, J = 7.7 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.7, 24.4, 37.5, 52.2, 116.4, 118.4, 119.0,

120.7, 121.9, 124.3, 129.8, 131.9, 140.3, 140.6, 147.2, 157.3, 166.4 ppm; HRMS (ESI-positive): calcd for $C_{17}H_{18}O_4$ ([M−H]$^+$): 285.1132, found: 285.1139.

2-(3-Hydroxymethyl-phenoxy)-5-propylphenol (38)

A mixture of 4-propyl-2-methoxyphenol (0.10 g, 0.6 mmol) and 3-(hydroxymethyl) phenylboronic acid (0.27 g, 1.8 mmol) was subjected to the general biaryl ether coupling procedure in method C above to obtain intermediate **38a** in 18% yield. A mixture of **38a** (0.03 g, 0.11 mmol), and BBr$_3$ (1M, 2.2 mL, 2.2 mmol) was subjected to the general demethylation procedure outlined in method D. The crude product was purified by preparative TLC (60% EtOAc/Hexanes) to afford 12 mg (42%) of **38**. ^{1}H NMR (300 MHz, CDCl$_3$): δ = 0.98 (t, J = 7.3 Hz, 3H), 1.78–1.62 (m, 2H), 2.57 (t, J = 7.4 Hz, 2H), 5.45 (s, 1H), 6.70 (dd, J = 8.0, J = 2.0 Hz, 1H), 6.84 (d, J = 8.2 Hz, 1H), 6.91 (d, J = 1.8 Hz, 1H), 6.94 (dd, J = 8.0, J = 2.0 Hz, 1H), 7.06 (d, J = 1.9 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 7.29 ppm (d, J = 8.8 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.8, 24.4, 32.7, 37.5, 116.2, 117.3, 117.9, 119.1, 120.7, 123.8, 125.8, 130.1, 139.7, 140.2, 140.5, 147.2, 157.4 ppm.

3-(2-Hydroxy-4-propylphenoxy)benzoic acid (39)

A mixture of **37** (0.02 g, 0.073 mmol), and LiOH·H$_2$O (0.03 g, 0.73 mmol) in methanol and water (5 mL + 5 mL) was stirred at rt for 2 h. The reaction mixture was acidified with saturated KHSO$_4$ solution, and extracted with EtOAc. The organic layer was washed with brine, dried over Na$_2$SO$_4$, filtered, and evaporated under reduced pressure. The residue was purified by preparative TLC using 1:10 MeOH/CH$_2$Cl$_2$ to afford 11 mg (55%) of **39**. ^{1}H NMR (300 MHz, CDCl$_3$): δ = 0.98 (t, J = 7.3 Hz, 3H), 1.70–1.60 (m, 2H), 2.57 (t, J = 7.5 Hz, 2H), 6.71 (dd, J = 8, J = 1 Hz, 1H), 6.84 (d, J = 8.2 Hz, 1H), 6.92 (d, J = 1.5 Hz, 1H), 7.27 (dd, J = 8, J = 2 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H), 7.74 (s, 1H), 7.86 ppm (d, J = 7.6 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.7, 24.4, 37.5, 116.4, 118.8, 119.1, 120.8, 122.8, 124.9, 129.9, 130.2, 131.0, 140.4, 147.2, 157.4, 171.2; HRMS (ESI-positive): calcd for $C_{16}H_{16}O_4$ ([M−H]$^+$): 271.0975, found: 271.0982.

1-[4-(2-Hydroxy-4-propylphenoxy)phenyl]ethanone (40)

General method D was employed to prepare the methoxy intermediate **40a** in 39% yield from 2-methoxy-4-propylphenol (0.10 g, 0.6 mmol), and 4-acetylphenylboronic acid (0.30 g, 1.8 mmol). A mixture of **40a** (0.06 g, 0.21 mmol), and BBr$_3$ (1M, 4.2 mL, 4.2 mmol) were subjected to the general demethylation procedure outlined in method D above. The crude product was purified by preparative TLC (40% EtOAc/Hexanes) to afford 42 mg (73%) of **40**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.98 (t, J = 7.2 Hz, 3H), 1.75–1.62 (m, 2H), 2.60–2.50 (m, 5H), 5.37 (s, 1H), 6.74 (d, J = 8.0 Hz, 1H), 6.90 (d, J = 8.5 Hz, 1H), 6.92 (s, 1H), 7.05 (d, J = 8.5 Hz, 2H), 7.96 ppm (d, J = 8.5 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.7, 24.4, 26.4, 37.5, 116.4, 116.6, 120.1, 120.9, 130.6, 132.2, 139.5, 141.1, 147.4, 161.5, 196.6 ppm; HRMS (ESI-positive): calcd for $C_{17}H_{18}O_3$ ([M−H]$^+$): 269.1183, found: 269.1188.

2-(4-Methylsulfanylphenoxy)-5-propylphenol (41)

A mixture of **41a** (0.05 g, 0.17 mmol) and BBr$_3$ (1M, 3.4 mL, 3.4 mmol) was subjected to the general demethylation procedure outlined in method D above. The crude product was purified by preparative TLC (40% EtOAc/Hexanes) to afford 32 mg of **41** (67%). ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.97 (t, J = 7.2 Hz, 3H), 1.72–1.62 (m, 2H), 2.49 (s, 3H), 2.56 (t, J = 6.4 Hz, 2H), 5.47 (s, 1H), 6.67 (d, J = 8.2 Hz, 1H), 6.80 (d, J = 8.2 Hz, 1H), 6.89 (s, 1H), 6.97 (d, J = 8.7 Hz, 2H), 7.29–7.27 ppm (m, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.7, 17.1, 24.4, 37.5, 116.1, 118.3, 118.6, 120.5, 125.8, 129.2, 132.3, 139.8, 141.1, 147.0, 155.2 ppm; HRMS (ESI-positive): calcd for $C_{16}H_{18}O_2S$ ([M−H]$^+$): 273.0954, found: 273.0958.

2-[4-(1-Hydroxyethyl)phenoxy]-5-propylphenol (42)

A mixture of **40** (0.02 g, 0.073 mmol) and NaBH$_4$ (.008 g, 0.22 mmol) was subjected to the general reduction procedure outlined above. The crude product was purified by preparative TLC (50% EtOAc/Hexanes) to afford 14 mg (69%) of **42**. ^{1}H NMR (300 MHz, CDCl$_3$): δ = 0.96 (t, J = 7.3 Hz, 3H), 1.70–1.55 (m, 2H), 2.56 (t, J = 7.4 Hz, 2H), 4.91 (q, J = 6.4 Hz, 1H), 5.50 (s, 1H), 6.67 (dd, J = 8, J = 2 Hz, 1H), 6.82 (d, J = 8.2 Hz, 1H), 6.89 (d, J = 1.7 Hz, 1H), 7.00 (d, J = 8.2 Hz, 2H), 7.35 ppm (d, J = 8.5 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.7, 24.4, 25.1, 37.5, 69.8, 116.1, 117.5, 118.9, 120.5, 126.9, 139.8, 140.7, 141.0, 147.1, 156.5 ppm; HRMS (ESI-positive): calcd for C$_{17}$H$_{20}$O$_3$ ([M–H]$^+$): 271.1339, found: 271.1342.

2-(4-Methanesulfinylphenoxy)-5-propylphenol (43)

A mixture of 2-methoxy-4-propylphenol (0.20 g, 1.2 mmol), and 4-(methylsulfanyl) phenylboronic acid (0.61 g, 3.61 mmol) were subjected to the general biaryl ether coupling procedure outlined in method C above to obtain intermediate **41a** in 59% yield. **41a** (0.15 g, 0.52 mmol) was subjected to oxidation using *m*-CPBA (80%, 0.17 g, 0.78 mmol, in 3 mL dichloromethane) in dichloromethane (20 mL) at 0 °C to afford 35 mg (22%) of **43a**, and 54 mg (32%) of **44a**. A mixture of **43a** (0.03 g, 0.098 mmol), and BBr$_3$ (1M, 1.9 mL, 1.9 mmol) was subjected to the general demethylation protocol described in method D above. The crude product was purified by preparative TLC (60% EtOAc/Hexanes) to afford 19 mg (66%) of **43**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.97 (t, J = 7.1 Hz, 3H), 1.70–1.58 (m, 2H), 2.57 (t, J = 6.7 Hz, 2H), 2.73 (s, 3H), 5.86 (s, 1H), 6.72 (d, J = 8.0 Hz, 1H), 6.88 (d, J = 8.1 Hz, 1H), 6.92 (s, 1H), 7.12 (d, J = 6.9 Hz, 2H), 7.60 ppm (d, J = 6.9 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.7, 24.4, 37.5, 43.9, 116.8, 117.6, 120.1, 120.8, 125.5, 138.9, 139.8, 141.0, 147.5, 160.1 ppm; HRMS (ESI-positive): calcd for C$_{16}$H$_{18}$O$_3$S ([M–H]$^+$): 289.0903, found: 289.0910.

2-(4-Methanesulfonylphenoxy)-5-propylphenol (44)

A mixture of **44a** (0.05 g, 0.15 mmol) and BBr$_3$ (1M, 3.1 mL, 3.1 mmol) was subjected to the general demethylation procedure outlined above in method D. The crude product was purified by preparative TLC (60% EtOAc in hexane) to afford 24 mg (50%) of **44**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.98 (t, J = 7.2 Hz, 3H), 1.75–1.65 (m, 2H), 2.59 (t, J = 6.6 Hz, 2H), 3.06 (s, 3H), 5.41 (s, 1H), 6.76 (d, J = 8 Hz, 1H), 6.91 (d, J = 8 Hz, 1H), 6.93 (s, 1H), 7.12 (d, J = 6.7 Hz, 2H), 7.89 (d, J = 6.6 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.7, 24.3, 37.5, 44.7, 116.9, 117.0, 120.4, 121.1, 129.7, 134.4, 139.1, 141.6, 147.4, 162.0 ppm; HRMS (ESI-positive): calcd for C$_{16}$H$_{18}$O$_4$S ([M–H]$^+$): 305.0853, found: 305.0858.

2-(3-Dimethylaminophenoxy)-5-propylphenol (45)

A mixture of **45b** (0.09 g, 0.31 mmol), and BBr$_3$ (1M, 6.3 mL, 6.3 mmol) was subjected to the general demethylation procedure outlined above. The crude product was purified by flash chromatography over *silica gel* (40% EtOAc/Hexanes) to afford 70 mg (81%) of **45.** ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.97 (t, J = 7.3 Hz, 3H), 1.68–1.63 (m, 2H), 2.56 (t, J = 7.5 Hz, 2H), 2.95 (s, 6H), 5.52 (s, 1H), 6.32 (d, J = 7.6 Hz, 1H), 6.44 (s, 1H), 6.49 (d, J = 8.3 Hz, 1H), 6.66 (d, J = 7.1 Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H), 6.86 (s, 1H), 7.18 ppm (t, J = 8.1 Hz, 2H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.4, 24.0, 37.1, 40.0, 101.7, 104.8, 107.2, 115.4, 118.4, 120.2, 129.6, 139.0, 140.9, 146.7, 151.6, 157.7 ppm; HRMS (ESI-positive): calcd for C$_{17}$H$_{21}$NO$_2$ ([M–H]$^+$): 270.1499, found: 270.1501.

5-Propyl-2-(3-trifluoromethylphenoxy)phenol (46)

A mixture of intermediate **46b** (0.08 g, 0.25 mmol) and BBr$_3$ (1M, 5.1 mL, 5.1 mmol) was subjected to the general demethylation procedure outlined above. The crude product was

purified by preparative TLC (40% EtOAc/Hexanes) to afford 45 mg (58%) of **46**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.98 (t, *J* = 7.3 Hz, 3H), 1.72–1.62 (m, 2H), 2.58 (t, *J* = 6.8 Hz, 2H), 5.40 (s, 1H), 6.72 (d, *J* = 8.1 Hz, 1H), 6.85 (d, *J* = 8.1 Hz, 1H), 6.92 (s, 1H), 7.17 (d, *J* = 8.1 Hz, 1H), 7.37 (d, *J* = 7.3 Hz, 1H), 7.45 ppm (t, *J* = 7.9 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.3, 24.0, 37.1, 113.9, 113.9, 116.1, 118.9, 119.4, 119.4, 119.9, 120.5, 121.8, 124.5, 130.0, 131.4, 131.7, 132.0, 139.7, 140.4, 146.8, 157.2 ppm; HRMS (ESI-positive): calcd for C$_{16}$H$_{19}$F$_3$O$_2$ ([M−H]$^+$): 295.0951, found: 295.0973.

3-(2-Hydroxy-4-propylphenoxy)benzaldehyde (47)

A mixture of **47a** (0.25 g, 0.92 mmol), and BBr$_3$ (1M, 18.4 mL, 18.4 mmol) was subjected to the general demethylation procedure outlined above. The crude product was purified by flash chromatography over *silica gel* (60% EtOAc/Hexanes) to afford 187 mg (78%) of **47**. ^{1}H NMR (300 MHz, CDCl$_3$): δ = 0.98 (t, *J* = 7.2 Hz, 3H), 1.70–1.63 (m, 2H), 2.57 (t, *J* = 6.7 Hz, 2H), 6.71 (dd, *J* = 8, *J* = 2 Hz, 1H), 6.85 (d, *J* = 8.3 Hz, 1H), 6.97 (d, *J* = 1.7 Hz, 1H), 7.32–7.29 (m, 1H), 7.49 (s, 1H), 7.53 (d, *J* = 7.9 Hz, 1H), 7.63 (d, *J* = 7.3 Hz, 1H), 9.98 (s, 1H) ppm.

3-[3-(2-Hydroxy-4-propylphenoxy)phenyl]acrylic acid methyl ester (48)

A mixture of **47** (0.18 g, 0.70 mmol), and methyl (triphenylphosphoranylidene) acetate (0.47 g, 1.40 mmol) in 20 mL of THF was refluxed overnight. The solvent was evaporated under reduced pressure. The residue was purified by *silica gel* column chromatography (1:3 EtOAc/Hexanes) to afford 177 mg (80%) of **48**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.98 (t, *J* = 7.3 Hz, 3H), 1.72–1.60 (m, 2H), 2.57 (t, *J* = 7.0 Hz, 2H), 3.82 (s, 3H), 5.43 (s, 1H), 6.40 (d, *J* = 16.0 Hz, 1H), 6.70 (d, *J* = 8.1 Hz, 1H), 6.84 (d, *J* = 8.1 Hz, 1H), 6.91 (s, 1H), 7.05 (d, *J* = 8.3 Hz, 1H), 7.16 (s, 1H), 7.36 (t, *J* = 7.8 Hz, 1H), 7.64 ppm (d, *J* = 16.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.7, 24.4, 37.5, 51.7, 116.3, 116.4, 118.7, 119.2, 120.7, 123.0, 130.2, 136.2, 140.3, 140.4, 144.0, 147.2, 157.7, 167.1 ppm; HRMS (ESI-positive): calcd for C$_{19}$H$_{20}$O$_4$ ([M−H]$^+$): 311.1288, found: 311.1299.

3-[3-(2-Hydroxy-4-propylphenoxy)phenyl]propionic acid methyl ester (49)

A mixture of **48** (0.10 g, 0.32 mmol) and 10% Pd/C (0.02 g) was subjected to the general hydrogenation to afford **49** (88 mg, 87%). ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.97 (t, *J* = 7.3 Hz, 3H), 1.69–1.62 (m, 2H), 1.64 (t, *J* = 7.8 Hz, 1H), 2.56 (t, *J* = 7.4 Hz, 2H), 2.63 (t, *J* = 7.9 Hz, 2H), 2.94 (t, *J* = 7.6 Hz, 2H), 5.47 (s, 1H), 3.68 (s, 3H), 6.68 (dd, *J* = 8, *J* = 2 Hz, 1H), 6.82 (d, *J* = 8.1 Hz, 1H), 6.87–6.85 (m, 2H), 6.89 (d, *J* = 1.5 Hz, 1H), 6.95 (d, *J* = 7.4 Hz, 1H), 7.25 ppm (t, *J* = 7.8 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.7, 24.4, 30.7, 35.4, 37.5, 51.6, 115.3, 116.0, 117.3, 118.9, 120.5, 123.1, 129.8, 139.8, 140.9, 142.6, 147.2, 157.3, 173.1 ppm; HRMS (ESI-positive): calcd for C$_{19}$H$_{22}$O$_4$ ([M−H]$^+$): 313.1445, found: 313.1451.

3-[3-(2-Hydroxy-4-propylphenoxy)phenyl]propionic acid (50)

A mixture of **48** (0.05 g, 0.16 mmol), and LiOH·H$_2$O (0.07 g, 1.62 mmol) was subjected to the hydrolysis reaction to afford acid **50** (29 mg, 60%). ^{1}H NMR (400 MHz, CDCl$_3$): δ = 0.98 (t, *J* = 7.3 Hz, 6H), 1.70–1.60 (m, 4H), 2.58 (t, *J* = 7.4 Hz, 4H), 6.41 (d, *J* = 16.0 Hz, 1H), 6.71 (d, *J* = 8.0 Hz, 1H), 6.85 (d, *J* = 8.0 Hz, 1H), 6.92 (s, 1H), 7.07 (d, *J* = 8.0 Hz, 1H), 7.18 (s, 1H), 7.29 (d, *J* = 8.0 Hz, 1H), 7.38 (t, *J* = 7.6 Hz, 1H), 7.62 ppm (d, *J* = 16.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.8, 24.4, 37.5, 116.4, 116.6, 118.1, 119.2, 119.6, 120.8, 123.2, 130.3, 135.8, 140.3, 140.4, 146.2, 147.2, 157.8, 171.7 ppm; HRMS (ESI-positive): calcd for C$_{18}$H$_{18}$O$_4$ ([M−H]$^+$): 297.1132, found: 297.1137.

3-[3-(2-Hydroxy-4-propylphenoxy)phenyl]propionic acid (51)

A mixture of **49** (0.05 g, 0.16 mmol), and LiOH·H$_2$O (0.07 g, 1.62 mmol) was subjected to the hydrolysis reaction to afford acid **51** (37 mg, 75%). ^{1}H NMR (300 MHz, CDCl$_3$): δ = 0.97 (t, J = 7.3 Hz, 3H), 1.72–1.60 (m, 2H), 2.56 (t, J = 7.4 Hz, 2H), 2.68 (t, J = 7.8 Hz, 2H), 2.95 (t, J = 7.5 Hz, 2H), 6.67 (dd, J = 8, J = 2 Hz, 1H), 6.82 (d, J = 8.2 Hz, 1H), 6.92–6.85 (m, 3H), 6.93 (d, J = 7.4 Hz, 1H), 7.24 ppm (d, J = 7.8 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 13.7, 24.4, 30.4, 35.1, 37.5, 115.4, 116.1, 117.4, 119.0, 120.5, 123.1, 129.8, 139.9, 140.8, 142.2, 147.2, 157.3, 177.7 ppm; HRMS (ESI-positive): calcd for C$_{18}$H$_{20}$O$_4$ ([M–H]$^+$): 299.1288, found: 299.1298.

3-[5-Chloro-2-(2,4-dichlorophenoxy)phenoxy]pyridine (52)

Method C was used to prepare **52**. A suspension of triclosan (0.10 g, 0.34 mmol), 3-pyridineboronic acid (0.13 g, 1.03 mmol), Cu(OAc)$_2$ (0.31 g, 1.72 mmol), Et$_3$N (0.35 g, 3.45 mmol) and 5 Å molecular sieves (0.6 g) in dichloromethane (20 mL) was stirred for 16 h at rt. Purification by preparative TLC using 1:3 EtOAc/Hexanes gave 45 mg (35%) of the title compound **52**. ^{1}H NMR (400 MHz, CDCl$_3$): δ = 6.83 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.6 Hz, 1H), 7.20–7.13 (m, 3H), 7.27–7.26 (m, 2H), 7.42 (d, J = 2.4 Hz, 1H), 8.33 (s, 1H), 8.39 ppm (d, J = 2.4 Hz, 1H); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 119.5, 121.1, 122.0, 124.0, 124.4, 125.5, 125.6, 127.9, 129.3, 129.9, 130.5, 140.2, 144.7, 145.8, 146.5, 150.8, 153.2 ppm; HRMS (ESI-positive): calcd for C$_{17}$H$_{11}$O$_2$N$_1$Cl$_3$ ([M + H]$^+$): 365.9849, found: 365.9843.

X-ray Crystallography

Details on the crystal structure of the triclosan–bound complex have been reported elsewhere.[46] The atomic coordinates and structure factors have been deposited in the Protein Data Bank (http://www.rcsb.org/pdb) under the PDB code 2QIO. Details on the crystal structure of *Ba*ENRI bound to inhibitors **11** and **43** will be reported elsewhere. A summary of crystallographic data collection and refinement information for these inhibitors is provided in the supporting information.

Computational Methods

All of the compounds synthesized in Tables 2–6 were docked using the GOLD docking program[58] into our *Ba*ENR crystal structure that was co–crystallized with triclosan. Within GOLD, the triclosan crystal structure was used as a reference ligand, and default parameters were chosen. The scoring function within GOLD chosen was ChemScore, after testing out numerous algorithms, and finding that ChemScore performed the best. A CoMFA was performed using up to 10 docking conformations of each of our ligands. Initial alignment of the compounds began by choosing the best scoring conformation. For each compound, multiple alternative conformations were systematically replaced to determine whether a better alignment could be achieved over the initial alignment, by way of a cross–validated PLS analysis. After all the conformations for one compound are evaluated, the conformation associated with the highest q^2 was kept in the alignment. Using a training set of 22 compounds, an acceptable model was found, shown by the PLS results of q^2 = 0.831, an r^2 = 0.929, and an SEE = 0.36. The steric and electrostatic fields were graphed and were used in the design of new compounds.

Purification of *Ba*ENR and Activity Assays

Enoyl reductase (ENR) from *Bacillus anthracis* was expressed and purified from *E. coli* according to the procedures of Klein et al.[46] The ENR reaction converts one molecule of NADH and crotonyl–CoA into NAD$^+$ and butyryl–CoA. The assay was conducted at 30 °C in a 96–well plate with 200 μL of buffer containing 20 mM Tris–HCl, 150 mM NaCl, 175

μM NADH, 200 μM crotonyl–CoA and 1 μM of purified BaENR. Crotonyl–CoA was added last to initiate the reaction. BaENR activity was recorded using a Molecular Devices SpectraMax384 Plus plate reader by measuring the decrease in NADH absorbance at 340 nm (ε = 6220 M^{-1} cm^{-1}). The path length of the well in the 96–well microtiter plate cell was determined by measuring the rate (ΔAU/min) in a 1 mL reaction volume with a 1.00 cm cuvette, and then calculating the rate of reaction (NADH/min) using the Beer–Lambert equation (AU = ε·L·[NADH]) where L = path length. The reaction was then split into 200 μL fractions, added to 5 wells of the 96–well plate, and the reaction rates were measured (ΔAU/min). The ΔAU/min values, in units of [NADH]/min, and the value of ε (6220 M^{-1} cm^{-1}) allowed us to determine a path length for the reactions of 0.45 cm.

Inhibition of BaENR by triclosan and other compounds

For the synthetic compounds, the maximum solubility of these compounds were determined first by adding 2 μL of a 10 mM stock solution of the compound that was dissolved in DMSO to the reaction well. The final volume was 200 μL, and if precipitation was visible in the reaction well, then sequential two–fold dilutions of the stock were created in DMSO and tested in the same manner until precipitation was no longer visible. Creating the stock solutions in this manner ensured a constant 1% (v/v) of DMSO to total solution. The percent inhibition (%I) was tested at the maximum solubility concentration using the equation %I = ((A_C − A_I)/A_C) * 100 where A_C = activity of the control (uninhibited) and A_I = activity with the inhibitor. If a percent inhibition value greater than 50% was attainable then the IC$_{50}$ values were determined. IC$_{50}$ values were determined by fixing the non–varied substrates at subsaturating concentrations as described above, and then varying the inhibitor concentrations. The reactions were allowed to preincubate for 30 minutes before adding crotonyl–CoA. An equal concentration of DMSO was added to the control experiments to negate the effect of solvent on enzyme activity. The data were fit to the equation %I = %I$_{max}$/(IC$_{50}$/[I]+1) using non–linear regression and the Enzyme Kinetics Module 1.0 of the program Sigma Plot (SYSTAT Inc).

Bacterial Growth and MIC Determination

The minimum inhibitory concentration (MIC) of triclosan and other compounds was tested against the *B. anthracis* ΔANR strain (plasmid–cured Ames Strain), Sterne strain *B. anthracis* and reference strains of the following bacteria: *Staphylococcus aureus* (ATCC strain **29213**), methicillin–resistant *Staphylococcus aureus* (ATCC strain **43300**), *Enterococcus fecalis* (ATCC strain **29212**), vancomycin–resistant *Enterococcus* (VRE) (ATCC strain **51299**), *Listeria monocytogenes* (**10403S**, provided by Nancy E. Freitag, University of Illinois, Chicago),[59] *Pseudomonas aeruginosa* (ATCC strain **27853**), *Klebsiella pneumoniae* (ATCC strain **700603**) and *Escherchia coli* (ATCC strain **25922**). Luria–Bertani (LB) medium was added to each well in a row on a sterile, Falcon MICROTEST™ 96–well U–bottom tissue culture plate; 96 μL was added to each well of the first column, and 50 μL was added to all subsequent wells. The compounds or control antibiotic to be tested were added to the first column for a final well volume of 100 μL. The inhibitors were then serially diluted (2–fold) across the columns of wells by pipetting and mixing 50 μL of solution; the extra 50 μL at the end of the row was discarded. Prior to setting up the MIC plates, the appropriate bacterial culture was grown to mid log–phase (OD$_{600}$ = 0.4–0.6) and subsequently diluted to OD$_{600}$ = 0.004 with fresh LB medium. 50 μL of the bacterial culture was added to each well of the plate and the plate was then incubated at 37 °C overnight (~14 h) without shaking. For each compound or antibiotic control, the first clear well with no signs of visible growth was reported as the MIC value. Medium from all clear wells was then inoculated onto plates of LB agar medium that were incubated overnight. The first clear–medium dilution from which no bacterial colonies could be grown was reported as the MBC value.

Acknowledgments

References

1. Infectious Disease Society of America. Bad Bugs, No Drugs. http://www.idsociety.org/WorkArea/showcontent.aspx?id=5554

2. Casey AL, Lambert PA, Elliott TS. Int J Antimicrob Agents. 2007; 29:S23–S32. [PubMed: 17659209]

3. Bancroft EA. J Am Med Assoc. 2007; 298:1803–1804.

4. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK. J Am Med Assoc. 2007; 298:1763–1771.

5. Weisblum B. Antimicrob Agents Chemother. 1995; 39:577–585. [PubMed: 7793855]

6. Bartlett JG, Inglesby TV Jr, Borio L. Clin Infect Dis. 2002; 35:851–858. [PubMed: 12228822]

7. Cavallo JD, Ramisse F, Girardet M, Vaissaire J, Mock M, Hernandez E. Antimicrob Agents Chemother. 2002; 46:2307–2309. [PubMed: 12069996]

8. Coker PR, Smith KL, Hugh–Jones ME. Antimicrob Agents Chemother. 2002; 46:3843–3845. [PubMed: 12435686]

9. Vester B, Douthwaite S. Antimicrob Agents Chemother. 2001; 45:1–12. [PubMed: 11120937]

10. Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA. J Biotechnol. 1996; 44:155–160. [PubMed: 8717399]

11. Price LB, Vogler A, Pearson T, Busch JD, Schupp JM, Keim P. Antimicrob Agents Chemother. 2003; 47:2362–2365. [PubMed: 12821500]

12. Athamna A, Athamna M, bu-Rashed N, Medlej B, Bast DJ, Rubinstein E. J Antimicrob Chemother. 2004; 54:424–428. [PubMed: 15205405]

13. MacIntyre CR, Seccull A, Lane JM, Plant A. Mil Med. 2006; 171:589–594. [PubMed: 16895121]

14. Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Emerg Infect Dis. 2002; 8:225–230. [PubMed: 11897082]

15. Burnett JC, Henchal EA, Schmaljohn AL, Bavari S. Nat Rev Drug Discov. 2005; 4:281–297. [PubMed: 15803193]

16. White SW, Zheng J, Zhang YM, Rock CO. Annu Rev Biochem. 2005; 74:791–831. [PubMed: 15952903]

17. Zhang YM, Lu YJ, Rock CO. Lipids. 2004; 39:1055–1060. [PubMed: 15726819]

18. Rock CO, Jackowski S. Biochem Biophys Res Commun. 2002; 292:1155–1166. [PubMed: 11969206]

19. Kobayashi K, Ehrlich SD, Albertini A, Amati G, Andersen KK, Arnaud M, Asai K, Ashikaga S, Aymerich S, Bessieres P, Boland F, Brignell SC, Bron S, Bunai K, Chapuis J, Christiansen LC, Danchin A, Dâebarbouille M, Dervyn E, Deuerling E, Devine K, Devine SK, Dreesen O, Errington J, Fillinger S, Foster SJ, Fujita Y, Galizzi A, Gardan R, Eschevins C, Fukushima T, Haga K, Harwood CR, Hecker M, Hosoya D, Hullo MF, Kakeshita H, Karamata D, Kasahara Y, Kawamura F, Koga K, Koski P, Kuwana R, Imamura D, Ishimaru M, Ishikawa S, Ishio I, Le Coq D, Masson A, Mauèel C, Meima R, Mellado RP, Moir A, Moriya S, Nagakawa E, Nanamiya H, Nakai S, Nygaard P, Ogura M, Ohanan T, O'Reilly M, O'Rourke M, Pragai Z, Pooley HM, Rapoport G, Rawlins JP, Rivas LA, Rivolta C, Sadaie A, Sadaie Y, Sarvas M, Sato T, Saxild HH, Scanlan E, Schumann W, Seegers JF, Sekiguchi J, Sekowska A, Sâeror SJ, Simon M, Stragier P, Studer R, Takamatsu H, Tanaka T, Takeuchi M, Thomaides HB, Vagner V, van Dijl JM, Watabe K, Wipat A, Yamamoto H, Yamamoto M, Yamamoto Y, Yamane K, Yata K, Yoshida K,

Yoshikawa H, Zuber U, Ogasawara N. Proc Natl Acad Sci U S A. 2003; 100:4678–4683. [PubMed: 12682299]

20. Heath RJ, Rock CO. J Biol Chem. 1995; 270:26538–26542. [PubMed: 7592873]

21. Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr, Sacchettini JC. Science. 1998; 279:98–102. [PubMed: 9417034]

22. Baldock C, de Boer GJ, Rafferty JB, Stuitje AR, Rice DW. Biochem Pharm. 1998; 55:1541–1549. [PubMed: 9633989]

23. Baldock C, Rafferty JB, Sedelnikova SE, Baker PJ, Stuitje AR, Slabas AR, Hawkes TR, Rice DW. Science. 1996; 274:2107–2110. [PubMed: 8953047]

24. Levy CW, Baldock C, Wallace AJ, Sedelnikova S, Viner RC, Clough JM, Stuitje AR, Slabas AR, Rice DW, Rafferty JB. J Mol Biol. 2001; 309:171–180. [PubMed: 11491286]

25. McMurry LM, McDermott PF, Levy SB. Antimicrob Agents Chemother. 1999; 43:711–713. [PubMed: 10049298]

26. Heath RJ, Yu YT, Shapiro MA, Olson E, Rock CO. J Biol Chem. 1998; 273:30316–30320. [PubMed: 9804793]

27. Levy CW, Roujeinikova A, Sedelnikova S, Baker PJ, Stuitje AR, Slabas AR, Rice DW, Rafferty JB. Nature. 1999; 398:383–384. [PubMed: 10201369]

28. McLeod R, Muench SP, Rafferty JB, Kyle DE, Mui EJ, Kirisits MJ, Mack DG, Roberts CW, Samuel BU, Lyons RE, Dorris M, Milhous WK, Rice DW. Int J Parasitol. 2001; 31:109–113. [PubMed: 11239932]

29. Moir DT. Curr Drug Targets Infect Disord. 2005; 5:297–305. [PubMed: 16181147]

30. He X, Alian A, Stroud R, Ortiz de Montellano PR. J Med Chem. 2006; 49:6308–6323. [PubMed: 17034137]

31. Broussy S, Bernardes-Gâenisson V, Quâemard A, Meunier B, Bernadou J. J Org Chem. 2005; 70:10502–10510. [PubMed: 16323864]

32. Miller WH, Seefeld MA, Newlander KA, Uzinskas IN, Burgess WJ, Heerding DA, Yuan CC, Head MS, Payne DJ, Rittenhouse SF, Moore TD, Pearson SC, Berry V, DeWolf WE Jr, Keller PM, Polizzi BJ, Qiu X, Janson CA, Huffman WF. J Med Chem. 2002; 45:3246–3256. [PubMed: 12109908]

33. Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE Jr, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF. J Med Chem. 2003; 46:1627–1635. [PubMed: 12699381]

34. Protasevich II, Brouillette CG, Snow ME, Dunham S, Rubin JR, Gogliotti R, Siegel K. Biochemistry. 2004; 43:13380–13389. [PubMed: 15491144]

35. Seefeld MA, Miller WH, Newlander KA, Burgess WJ, Payne DJ, Rittenhouse SF, Moore TD, DeWolf WE Jr, Keller PM, Qiu X, Janson CA, Vaidya K, Fosberry AP, Smyth MG, Jaworski DD, Slater-Radosti C, Huffman WF. Bioorg Med Chem Lett. 2001; 11:2241–2244. [PubMed: 11527706]

36. a) Karlowsky JA, Laing NM, Baudry T, Kaplan N, Vaughan D, Hoban DJ, Zhanel GG. Antimicrob Agents Chemother. 2007; 51:1580–1581. [PubMed: 17220418] b) Park HS, Yoon YM, Jung SJ, Yun INR, Kim CM, Kim JM, Kwak J-H. Int J Antimicrob Ag. 2007; 30:446–451.

37. Sivaraman, Sullivan TJ, Johnson F, Novichenok P, Cui G, Simmerling C, Tonge PJ. J Med Chem. 2004; 47:509–518. [PubMed: 14736233]

38. Escalada MG, Harwood JL, Maillard JY, Ochs D. J Antimicrob Chemother. 2005; 55:879–882. [PubMed: 15860550]

39. McMurry LM, Oethinger M, Levy SB. Nature. 1998; 394:531–532. [PubMed: 9707111]

40. Regèos J, Zak O, Solf R, Vischer WA, Weirich EG. Dermatol. 1979; 158:72–79.

41. a) Freundlich JS, Anderson JW, Sarantakis D, Shieh HM, Yu M, Valderramos JC, Lucumi E, Kuo M, Jacobs WR Jr, Fidock DA, Schiehser GA, Jacobus DP, Sacchettini JC. Bioorg Med Chem Lett. 2005; 15:5247–5252. [PubMed: 16198563] b) Freundlich JS, Wang F, Han-Chun Tsai, Kuo M, Hong-Ming Shieh, Anderson JW, Nkrumah LJ, Valderramos Juan-Carlos, Yu M, Kumar TRS,

Valderramos SG, Jacobs WR Jr, Schiehser GA, Jacobus DP, David P, Fidock DA, Sacchettini JC. J Biol Chem. 2007; 282:25436–25444. [PubMed: 17567585]

42. Freundlich JS, Yu M, Lucumi E, Kuo M, Tsai HC, Valderramos JC, Karagyozov L, Jacobs WR Jr, Schiehser GA, Fidock DA, Jacobus DP, Sacchettini JC. Bioorg Med Chem Lett. 2006; 16:2163–2169. [PubMed: 16466916]

43. a) Lu H, Tonge PJ. Acc Chem Res. 2008; 41:11–20. [PubMed: 18193820] b) Sullivan TJ, Truglio JJ, Boyne ME, Novichenok P, Zhang X, Stratton CF, Li HJ, Kaur T, Amin A, Johnson F, Slayden RA, Kisker C, Tonge PJ. ACS Chem Biol. 2006; 1:43–53. [PubMed: 17163639]

44. Perozzo R, Kuo M, Sidhu AS, Valiyaveettil JT, Bittman R, Jacobs WR Jr, Fidock DA, Sacchettini JC. J Biol Chem. 2002; 277:13106–13114. [PubMed: 11792710]

45. Chhibber M, Kumar G, Parasuraman P, Ramya TN, Surolia N, Surolia A. Bioorg Med Chem. 2006; 14:8086–8098. [PubMed: 16893651]

46. Klein GM, Bernard DS, Tipparaju SK, Pegan S, Bishop MH, Kozikowski AP, Mesecar AD. Biochemistry. 2007 Accepted with minor revisions.

47. Evans DA, Katz JL, West TR. Tetrahedron Lett. 1998; 39:2937–2940.

48. Papamicael C, Queguiner G, Bourguignon J, Dupas G. Tetrahedron. 2001; 57:5385–5391.

49. Su-Dong, Cho; Yong-Dae, Park; Jeum-Jong, Kim; Falck, JR.; Yoon, Y-J. Bull Korean Chem Soc. 2004; 25:407–409.

50. Molecular properties were calculated using a free web-based program (http://146.107.217.178/lab/alogps/index.html). A table showing comparision of values of synthesized compounds with those of triclosan is included in supplementary material.

51. Boyne ME, Sullivan TJ, amEnde CW, Lu H, Gruppo V, Heaslip D, Amin AG, Chatterjee D, Lenaerts A, Tonge PJ, Slayden RA. Antimicrob Agents Chemother. 2007; 51:3562–3567. [PubMed: 17664324]

52. Auffinger P, Hays FA, Westhof E, Ho PS. Proc Natl Acad Sci U S A. 2004; 101:16789–16794. [PubMed: 15557000]

53. Pidugu LS, Kapoor M, Surolia N, Surolia A, Suguna K. J Mol Biol. 2004; 343:147–155. [PubMed: 15381426]

54. Tipparaju SK, Joyasawal S, Forrester S, Mulhearn DC, Pegan S, Johnson ME, Mesecar AD, Kozikowski AP. Bioorg Med Chem Lett. 2008 in press.

55. Kapoor M, Mukhi PL, Surolia N, Suguna K, Surolia A. Biochem J. 2004; 381:725–733. [PubMed: 15125687]

56. Lambert RJ. J Appl Microbiol. 2004; 97:699–6711. [PubMed: 15357719]

57. Suller MT, Russell AD. J Antimicrob Chemother. 2000; 46:11–8. [PubMed: 10882683]

58. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Proteins. 2003; 52:609–623. [PubMed: 12910460]

59. Mueller KJ, Freitag NE. Infect Immun. 2005; 73:1917–1926. [PubMed: 15784531]

Figure 1.
Comparisons of ligand–bound crystal structures of *Ba*ENR: side chains are shaded gray, NAD$^+$ is shaded blue–gray (behind the ligand). (A) The triclosan crystal structure is shaded in coral. The GOLD docking conformation for triclosan is in cyan. (B) Compound **11** crystal structure is shaded coral and GOLD conformation is cyan. (C) Compound **43** crystal structure is shown in coral and the GOLD conformation is cyan. Hydrogen bonding is shown in green, between the ligands and Tyr 157, as well as the multiple hydrogen bonding of the 2′-hydroxyl of NAD$^+$ with both the 2-hydroxy and the ether linkage of the ligands. Also shown is a hydrogen bond between 2′-chloro of triclosan and Ser 197.

Figure 2.
Surface maps of the *Ba*ENR active site. **(A)** Electrostatic Potential surface map, areas shaded orange/yellow indicates regions of moderate positive charge on *Ba*ENR, whereas cyan shading indicates areas of neutral charge. **(B)** Lipophilic map, with a brown to green scale, where brown depicts the more hydrophobic areas. **(C)** Hydrogen bonding map, where the blue and red areas indicate places for either hydrogen bonding acceptors or donors, respectively. **(D)** Steric and electrostatic fields from CoMFA based on IC_{50} values. Steric fields are green and yellow, indicating regions of favorable and unfavorable steric expansion. Electrostatic fields are red and blue, indicating preferred regions of negative and positive charge. Surface maps were generated using the Benchware software and CoMFA fields are generated within Sybyl 7.2, both softwares from Tripos, Inc., St. Louis, MO.

Figure 3.
SAR of diaryl ether *Ba*ENR inhibitors.

Scheme 1.
Synthesis of compounds **1–17**: When X = F and $R^4 = R^5$ = H, NO$_2$, CN, Cl, Method A: K$_2$CO$_3$, DMSO, 100 °C, 8–12 h. When X = Br or I and $R^4 = R^5$ = H, OMe, Ph, Method B: KOtBu, DMF, (CuOTf)$_2$·PhH, 140 °C, 16–20 h. a) BH$_3$·THF, 3M NaOH, H$_2$O$_2$, rt, 4–6 h; b) Excess BBr$_3$, CH$_2$Cl$_2$, −78 °C to rt, 2–6 h; c) 35% H$_2$O$_2$, 3N NaOH, EtOH, 30 °C, 18 h; d) **14a**, 25% NaOH, EtOH, reflux, 20 h; e) NaBH$_4$, BF$_3$·Et$_2$O, THF, rt to reflux, 1 h.

Scheme 2.
Synthesis of compounds **18**–**22**: a) Pd/C, H_2, EtOH, rt, 2–6 h; b) Ac_2O, DMAP, Et_3N, CH_2Cl_2, rt, 3–6 h; c) Excess BBr_3, CH_2Cl_2, −78 °C to rt, 2–6 h; d) 4-toluenesulfonyl chloride, Et_3N, CH_2Cl_2, 0 °C to rt, 3 h.

Scheme 3.
Synthesis of compounds **23**–**25**: a) Method B: KO*t*Bu, DMF, (CuOTf)$_2$·PhH, 140 °C, 14–18 h; b) Excess BBr$_3$, CH$_2$Cl$_2$, −78 °C to rt, 2–6 h.

Scheme 4.
Synthesis of compounds **26–31**: a) Phenylboronic acid, Cu(OAc)$_2$, Et$_3$N, CH$_2$Cl$_2$, air, rt, 16 h; b) OsO$_4$, NMO, THF, rt, overnight; c) BBr$_3$, CH$_2$Cl$_2$, −78 °C, 2h; d) H$_2$, Pd/C, EtOAc, rt, 2h; e) NaBH$_4$, MeOH, 0 °C, 1h; f) amine, NaBH(OAc)$_3$, AcOH, CH$_2$Cl$_2$, rt, overnight.

Scheme 5.
Synthesis of compounds **32**–**35**: a) Cu(OAc)$_2$, *meta*- or *para*-phenyldiboronic acid, Et$_3$N, CH$_2$Cl$_2$, air, rt, 16 h; b) BBr$_3$, CH$_2$Cl$_2$, −78 °C, 2h.

Scheme 6.
Synthesis of compounds **36–46**: a) Cu(OAc)$_2$, substituted phenylboronic acids, Et$_3$N, CH$_2$Cl$_2$, air, rt, 16 h; b) BBr$_3$, CH$_2$Cl$_2$, −78 °C to rt, 2h; c) *m*-CPBA, CH$_2$Cl$_2$, 0 °C, 10 min; d) NaBH$_4$, MeOH, 0 °C, 1h; e) LiOH·H$_2$O, MeOH, H$_2$O, rt, 2h; f) H$_2$, Pd/C, EtOAc, rt, 2h.

Scheme 7.
Synthesis of compounds **47**–**51**: a) Cu(OAc)$_2$, 3-formylphenylboronic acid, Et$_3$N, CH$_2$Cl$_2$, air, rt, 16 h; b) BBr$_3$, CH$_2$Cl$_2$, −78 °C to rt, 2h; c) Ph$_3$P=CHCO$_2$Me, THF, reflux, overnight; d) H$_2$, Pd/C, EtOAc, rt, 2h; e) LiOH·H$_2$O, MeOH, H$_2$O, rt, 2h.

Table 1

Ba ENR inhibition and antibacterial activity for modifications of ring A.

| Compound	R^1	R^2	IC$_{50}$ (μM) or % inhibition at 1μM	MIC$^{[b]}$ (μg/mL)
Triclosan			0.6 ± 0.0	3.1
52	Cl	(pyridinyloxy group)	0.5%	NT
53	Cl	OMe	0%	NT
54	Cl	NH$_2$	4.4%	NT
14	Cl	CO$_2$H	0%	NT
16	Cl	CH$_2$OH	1.8%	NT
17	Cl	CONH$_2$	0%	NT
55	Cl	OH	0.5 ± 0.1	32
1	OH	OH	6.3 ± 0.4	64
2	NO$_2$	OH	>50	5.8
26	CH$_2$CH(OH)CH$_2$OH	OH	9.8%	>104
28	CH$_2$OH	OH	5.0%	43
29	CH$_2$NHCH(CH$_3$)CH$_2$CH$_2$CH$_3$	OH	0%	>109
30	CH$_2$–(1–piperidine)	OH	0%	>113
31	CH$_2$NHCH$_2$Ph	OH	7.9%	>122
27	*n*-propyl	OH	>0.8$^{[a]}$	22.8

[a] Saturation with inhibitor was not obtained over the concentration range tested. The percent inhibition of *Ba*ENR showed a linear response to increasing inhibitor concentrations.

[b] MIC values are against ΔANR *B. anthracis*. NT = Not tested.

Table 2

Ba ENR inhibition and antibacterial activity for modification of ring B.

Compound	ortho	meta	para	IC$_{50}$ (μM) or %inhibition at 1μM	MIC[b] (μg/mL)
Triclosan	Cl	---	Cl	0.6 ± 0.0	3.1
55	---	---	---	0.5 ± 0.1	32
3	---	---	OH	2.6%	>64
20	---	---	NH$_2$	7.1 ± 1.2	12
18	---	---	(NHC(O)CH$_3$)	1.6%	111
19	(NHC(O)CH$_3$)	---	---	0%	111
22	---	---	(NHSO$_2$–C$_6$H$_4$–CH$_3$)	>12[a]	4.9
4	---	---	NO$_2$	7.2%	3.3
5	NO$_2$	---	---	7.7 ± 0.7	13.3
6	Cl	---	NO$_2$	0.3 ± 0.0	<0.1 – 3.1
7	---	---	Ph	>6.25	1.9

Compound	ortho	meta	para	IC$_{50}$ (μM) or %inhibition at 1μM	MIC[b] (μg/mL)
32	---	---		15.5%	>145
33	---			9.9%	2.3

[a] Saturation with inhibitor was not obtained over the concentration range tested. The percent inhibition of *Ba*ENR showed a linear response to increasing inhibitor concentrations.

[b] MIC values are against ΔANR *B. anthracis.*

Table 3

Ba ENR inhibition and antibacterial activity for modification of ring B, where ring A is a 2-hydroxy-4-propylphenyl group.

Compound	ortho	meta	para	IC$_{50}$ (μM) or % inhibition at 1 μM	MIC[c] (μg/mL)
Triclosan				0.6 ± 0.0	3.1
27	---	---	---	>0.8[a]	22.8
8	---	---	NO$_2$	1.1 ± 0.1	3.4
9	---	NO$_2$	---	>0.8[a]	1.7
10	NO$_2$	---	NO$_2$	3.6 ± 0.8	4
11	Cl	---	NO$_2$	0.5 ± 0.0	1.9–3.1
12	Cl	---	CN	>0.8[a]	1.8
15	Cl	---	–C(=O)NH$_2$	1.1 ± 0.1	30.6
40	---	---	–C(=O)Me	0.8 ± 0.1	13.5
43	---	---	–S(=O)Me	3.6 ± 0.3	116
44	---	---	–SO$_2$Me	2.2 ± 0.3	61.3
42	---	---	CH(OH)Me	17.1%	54.5
21	---	---	NH$_2$	8.8 ± 1.0	>97
41	---	---	SMe	0.6 ± 0.0	13.5
45	---	N(Me)$_2$	---	12.6%	13.6
46	---	CF$_3$	---	1.24	7.4
37	---	CO$_2$Me	---	2.0 ± 0.3	3.6
39	---	CO$_2$H	---	9.2%	6.8
38	---	CH$_2$OH	---	20.3 ± 1.3	12.9
36	---	Ph	---	0.5 ± 0.1[b]	1.9

Compound	ortho	meta	para	IC$_{50}$ (μM) or % inhibition at 1μM	MIC[c] (μg/mL)
34	---	OH, O (structure)	---	20.6%	1.2
35	---	---	OH, O (structure)	10.0%	>151
48	---	O-CH$_3$, O (structure)	---	>6.25	2
49	---	CH$_2$CH$_2$CO$_2$Me	---	7.5 ± 1.9	7.9
50	---	CH=CHCO$_2$H	---	17.9%	14.9
51	---	CH$_2$CH$_2$CO$_2$H	---	17.6%	60.1
13	---	CH$_2$CH$_2$Br	---	6.0 ± 1.5	1.7

[a]Saturation with inhibitor was not obtained over the concentration range tested. The percent inhibition of *Ba*ENR showed a linear response to increasing inhibitor concentrations.

[b]100% inhibition was not observed. The response of the enzyme to inhibitor showed maximum saturation at ~50% inhibition.

[c]MIC values are against ΔANR *B. anthracis.*

Table 4

MICs and MBCs of ENR inhibitors against *B. anthracis* and other bacterial pathogens.

Bacteria	Cipro[a] MIC[b]	Compound 6[e] MIC	MBC	MBC/MIC	Compound 11[e] MIC	MBC	MBC/MIC
ΔANR[c]	0.1 ± 0.0	2.2 ± 0.4	3.1 ± 1.1	1.4	2.2 ± 0.0	3.9 ± 0.8	1.8
Sterne[d]	0.1 ± 0.0	1.9 ± 0.3	3.9 ± 0.8	2.1	1.9 ± 0.0	3.9 ± 0.8	2.1
S. aureus	0.4 ± 0.0	0.1 ± 0.1	2.9 ± 1.2	20.9	0.1 ± 0.1	2.9 ± 1.2	20.9
MRSA	0.5 ± 0.2	0.3 ± 0.3	0.4 ± 0.1	1.6	0.3 ± 0.3	0.5 ± 0.2	1.9
E. fecalis	0.7 ± 0.1	4.4 ± 0.8	31.3 ± 6.3	7.1	4.4 ± 0.5	12.5 ± 0.0	2.9
VRE	0.6 ± 0.2	5.7 ± 0.6	37.5 ± 12.5	6.6	5.7 ± 0.3	15.6 ± 3.1	2.7
Listeria mono.	0.9 ± 0.3	2.8 ± 0.3	14.1 ± 3.9	5.0	2.8 ± 0.9	14.1 ± 3.9	5.0
Pseud. aerug.	0.3 ± 0.1	>25	NT		>25	NT	
Klebs. pneum.	0.5 ± 0.1	1.8 ± 0.4	12.5	7.1	1.8 ± 0.9	8.3 ± 2.1	4.7
E. coli	0.1 ± 0.0	0.3 ± 0.1	12.50	48.0	0.3 ± 0.2	1.2 ± 0.4	4.5

[a] Drug concentrations = µg/mL. Results = mean ± SEM, n = 3.

[b] MIC = minimum inhibitory concentration; MBC = minimum bactericidal concentration; MBC/MIC: bactericidal drug ≤ 4.

[c] Plasmid-negative strain of anthrax, lacking both pXO1 and pXO2 plasmids.

[d] Sterne strain of anthrax that contains pXO1 (toxin production) but lacks pXO2 (capsule).

[e] The EC50 against HeLa cells is 29.3 µg/mL for **6** and 41.4 µg/mL for **11**. EC50 against MHS is 9.9 µg/mL for **6** and 22.6 µg/mL for **11**.